[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f8AiC7FqCgWhkPeoCAvjY5xjR3HU8csONnhG818MOC5E":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"University of Kansas Medical Center",[4],484,false,138,12,67745,51,343,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Breast Cancer",21,{"name":18,"count":19},"Obesity",17,{"name":21,"count":22},"Bladder Cancer",14,{"name":24,"count":9},"Alzheimer Disease",{"name":26,"count":27},"Smoking Cessation",11,{"name":29,"count":27},"Dementia",{"name":31,"count":32},"Prostate Cancer",9,{"name":34,"count":35},"Hypertension",8,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT04046094","Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients","2022-09-12","Ascorbic Acid",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT05609253","Itraconazole to Prevent Recurrent Barrett's Esophagus","2024-02-23","Itraconazole in capsule form",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03488667","Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma","2024-04-30","Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT05638698","Tg01 Vaccine \u002F Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer","2024-12","TG01 Vaccine",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05143229","Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer","2025-01-28","Alpelisib",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05915351","Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)","2025-06-01","Enfortumab vedotin",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT06129851","Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer","2025-10-23","Relugolix",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04781192","The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers","2025-11-12","Durvalumab",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT06178588","Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma","2026-03-01","Sacituzumab Govitecan",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06736717","Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer","2026-07","Onvansertib",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,152,170,198,216,270,309,355,384,409,455,514,575,601,639,674,720,742,777,799,824,849,874,892,914,932,958,983,1001,1022,1040,1064,1082,1106,1124,1142,1165,1187,1214,1232,1260,1278,1296,1319,1337,1362,1380,1405,1423,1441,1502,1524,1572,1607,1629,1667,1697,1727,1752,1770,1796,1814,1839,1867,1885,1903,1927,1945,1963,1981,1999,2022,2047,2065,2090,2114,2132,2160,2178,2196,2214,2232,2260,2278,2296,2328,2346,2364,2390,2408,2433,2451,2469,2512,2549,2583,2601,2619,2637,2655,2676,2694,2720,2738,2765,2783,2801,2825,2843,2861,2884,2909,2940,2958,2976,2994,3012,3030,3048,3072,3094,3117,3143,3168,3193,3217,3235,3259,3285,3303,3321,3339,3362,3386,3409,3427,3445,3471,3489,3507,3531,3549,3571,3595,3619,3642,3665,3691,3709,3735,3753,3779,3797,3821,3846,3864,3889,3913,3931,3953,3977,4001,4022,4045,4067,4085,4117,4135,4160,4184,4210,4234,4252,4286,4311,4334,4355,4379,4404,4422,4440,4463,4489,4515,4533,4559,4577],{"intervention":96,"totalTrials":97,"cells":98},"Tranexamic Acid",3,{"EARLY_PHASE1":99,"PHASE1":102,"PHASE2":104,"PHASE3":106,"PHASE4":122,"NA":150},{"trials":100,"activeCount":101},[],0,{"trials":103,"activeCount":101},[],{"trials":105,"activeCount":101},[],{"trials":107,"activeCount":101},[108],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":114,"start":115,"enrollment":101,"conditions":116,"interventions":120},"NCT06638749","Effect of TXA on Blood Loss in Reverse Total Shoulder Arthroplasty","WITHDRAWN",[91],"2020-12-01","2024-10-10","2019-05-01",[117,118,119],"Shoulder Arthritis","Blood Loss, Surgical","Tranexamic Acid Adverse Reaction",[96,121],"Normal Saline",{"trials":123,"activeCount":149,"soonestReadout":140},[124,135],{"nctId":125,"briefTitle":126,"status":127,"phases":128,"primaryCompletion":129,"completion":129,"start":130,"enrollment":9,"conditions":131,"interventions":134},"NCT04347122","Tranexamic Acid in Radical Resection and Endoprosthetic Reconstruction","TERMINATED",[92],"2023-08-18","2020-01-28",[132,133],"Musculoskeletal Cancer","Sarcoma,Soft Tissue",[96],{"nctId":136,"briefTitle":137,"status":138,"phases":139,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":146},"NCT06379724","Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft","RECRUITING",[92],"2026-12","2024-07-11",62,[144,145],"Burns","Skin Graft Complications",[147,148],"Tranexamic acid","Thrombin JMI",1,{"trials":151,"activeCount":101},[],{"intervention":148,"totalTrials":149,"cells":153},{"EARLY_PHASE1":154,"PHASE1":156,"PHASE2":158,"PHASE3":160,"PHASE4":162,"NA":168},{"trials":155,"activeCount":101},[],{"trials":157,"activeCount":101},[],{"trials":159,"activeCount":101},[],{"trials":161,"activeCount":101},[],{"trials":163,"activeCount":149,"soonestReadout":140},[164],{"nctId":136,"briefTitle":137,"status":138,"phases":165,"primaryCompletion":140,"completion":140,"start":141,"enrollment":142,"conditions":166,"interventions":167},[92],[144,145],[147,148],{"trials":169,"activeCount":101},[],{"intervention":171,"totalTrials":149,"cells":172},"triamcinolone acetonide extended-release injectable suspension; TCA-ER",{"EARLY_PHASE1":173,"PHASE1":175,"PHASE2":177,"PHASE3":179,"PHASE4":181,"NA":196},{"trials":174,"activeCount":101},[],{"trials":176,"activeCount":101},[],{"trials":178,"activeCount":101},[],{"trials":180,"activeCount":101},[],{"trials":182,"activeCount":149,"soonestReadout":187},[183],{"nctId":184,"briefTitle":185,"status":138,"phases":186,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":194},"NCT06478186","Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes",[92],"2026-12-16","2027-01-16","2024-08-16",120,[192,193],"Osteoarthritis, Knee","Diabetes Mellitus, Type 2",[171,195],"Triamcinolone Acetonide- Immediate Release;TCA-IR",{"trials":197,"activeCount":101},[],{"intervention":195,"totalTrials":149,"cells":199},{"EARLY_PHASE1":200,"PHASE1":202,"PHASE2":204,"PHASE3":206,"PHASE4":208,"NA":214},{"trials":201,"activeCount":101},[],{"trials":203,"activeCount":101},[],{"trials":205,"activeCount":101},[],{"trials":207,"activeCount":101},[],{"trials":209,"activeCount":149,"soonestReadout":187},[210],{"nctId":184,"briefTitle":185,"status":138,"phases":211,"primaryCompletion":187,"completion":188,"start":189,"enrollment":190,"conditions":212,"interventions":213},[92],[192,193],[171,195],{"trials":215,"activeCount":101},[],{"intervention":217,"totalTrials":97,"cells":218},"Pembrolizumab",{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":252,"PHASE4":266,"NA":268},{"trials":220,"activeCount":101},[],{"trials":222,"activeCount":101},[],{"trials":224,"activeCount":149,"soonestReadout":140},[225,240],{"nctId":226,"briefTitle":227,"status":228,"phases":229,"primaryCompletion":140,"completion":230,"start":231,"enrollment":232,"conditions":233,"interventions":235},"NCT05645380","Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC","ACTIVE_NOT_RECRUITING",[90],"2028-12","2022-12-05",139,[234,15],"Triple Negative Breast Cancer",[236,237,238,239,217],"Carboplatin","Docetaxel","Doxorubicin","Cyclophosphamide",{"nctId":241,"briefTitle":242,"status":243,"phases":244,"primaryCompletion":245,"completion":246,"start":247,"enrollment":190,"conditions":248,"interventions":250},"NCT03639948","Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer","UNKNOWN",[90],"2022-01-27","2024-11","2018-09-04",[249],"Triple-negative Breast Cancer",[236,237,217,251],"Pegfilgrastim",{"trials":253,"activeCount":149,"soonestReadout":258},[254],{"nctId":255,"briefTitle":256,"status":138,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":264},"NCT07174453","Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies",[91],"2027-10-01","2029-10-01","2025-10-07",192,[263],"Solid Tumor Malignancies",[265,217],"Nivolumab",{"trials":267,"activeCount":101},[],{"trials":269,"activeCount":101},[],{"intervention":265,"totalTrials":97,"cells":271},{"EARLY_PHASE1":272,"PHASE1":274,"PHASE2":276,"PHASE3":299,"PHASE4":305,"NA":307},{"trials":273,"activeCount":101},[],{"trials":275,"activeCount":101},[],{"trials":277,"activeCount":101},[278,291],{"nctId":279,"briefTitle":280,"status":243,"phases":281,"primaryCompletion":282,"completion":55,"start":283,"enrollment":284,"conditions":285,"interventions":288},"NCT03995017","Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma",[89,90],"2022-10-19","2020-01-09",34,[286,287],"Esophagus Cancer, Adenocarcinoma","Stomach Cancer, Adenocarcinoma",[289,290,265],"Rucaparib","Ramucirumab",{"nctId":292,"briefTitle":293,"status":111,"phases":294,"primaryCompletion":295,"enrollment":101,"conditions":296,"interventions":298},"NCT02962804","Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)",[90],"2017-02-02",[297],"Carcinoma, Renal Cell",[265],{"trials":300,"activeCount":149,"soonestReadout":258},[301],{"nctId":255,"briefTitle":256,"status":138,"phases":302,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":303,"interventions":304},[91],[263],[265,217],{"trials":306,"activeCount":101},[],{"trials":308,"activeCount":101},[],{"intervention":310,"totalTrials":97,"cells":311},"Bupropion",{"EARLY_PHASE1":312,"PHASE1":314,"PHASE2":316,"PHASE3":318,"PHASE4":351,"NA":353},{"trials":313,"activeCount":101},[],{"trials":315,"activeCount":101},[],{"trials":317,"activeCount":101},[],{"trials":319,"activeCount":149,"soonestReadout":324},[320,330,342],{"nctId":321,"briefTitle":322,"status":138,"phases":323,"primaryCompletion":324,"completion":325,"start":326,"enrollment":327,"conditions":328,"interventions":329},"NCT05732272","Improving Smoking Abstinence Outcomes in the African American Community Through Extended Treatment",[91],"2027-01-31","2027-04-30","2023-02-28",500,[26],[310],{"nctId":331,"briefTitle":332,"status":333,"phases":334,"primaryCompletion":335,"completion":336,"start":115,"enrollment":337,"conditions":338,"interventions":339},"NCT03897439","Individualizing Pharmacotherapy for African American Smokers","COMPLETED",[91],"2021-11-30","2022-01-30",392,[26],[340,341,310],"Nicotine patch","Varenicline Tartrate",{"nctId":343,"briefTitle":344,"status":333,"phases":345,"primaryCompletion":346,"completion":346,"start":347,"enrollment":348,"conditions":349,"interventions":350},"NCT00440115","Disease Management for Smoking Cessation",[91],"2010-12","2009-06",750,[26],[310],{"trials":352,"activeCount":101},[],{"trials":354,"activeCount":101},[],{"intervention":341,"totalTrials":356,"cells":357},2,{"EARLY_PHASE1":358,"PHASE1":360,"PHASE2":362,"PHASE3":364,"PHASE4":380,"NA":382},{"trials":359,"activeCount":101},[],{"trials":361,"activeCount":101},[],{"trials":363,"activeCount":101},[],{"trials":365,"activeCount":149,"soonestReadout":370},[366,376],{"nctId":367,"briefTitle":368,"status":138,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":327,"conditions":373,"interventions":375},"NCT05703672","Switching to E-cigarettes in Smokers Not Interested in Quitting",[91],"2026-12-07","2027-02-28","2023-07-17",[374],"Smoking Reduction",[341],{"nctId":331,"briefTitle":332,"status":333,"phases":377,"primaryCompletion":335,"completion":336,"start":115,"enrollment":337,"conditions":378,"interventions":379},[91],[26],[340,341,310],{"trials":381,"activeCount":101},[],{"trials":383,"activeCount":101},[],{"intervention":385,"totalTrials":149,"cells":386},"Sirolimus",{"EARLY_PHASE1":387,"PHASE1":389,"PHASE2":391,"PHASE3":393,"PHASE4":405,"NA":407},{"trials":388,"activeCount":101},[],{"trials":390,"activeCount":101},[],{"trials":392,"activeCount":101},[],{"trials":394,"activeCount":149,"soonestReadout":399},[395],{"nctId":396,"briefTitle":397,"status":228,"phases":398,"primaryCompletion":399,"completion":399,"start":400,"enrollment":401,"conditions":402,"interventions":404},"NCT04789070","Phase III Trial of Sirolimus in IBM",[91],"2027-12","2022-07-01",140,[403],"Inclusion Body Myositis",[385],{"trials":406,"activeCount":101},[],{"trials":408,"activeCount":101},[],{"intervention":41,"totalTrials":97,"cells":410},{"EARLY_PHASE1":411,"PHASE1":428,"PHASE2":430,"PHASE3":438,"PHASE4":440,"NA":442},{"trials":412,"activeCount":149,"soonestReadout":417},[413],{"nctId":414,"briefTitle":415,"status":138,"phases":416,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":423},"NCT04832009","Reversing Glucose and Lipid-mediated Vascular Dysfunction",[88],"2026-08-01","2027-08-01","2022-05-09",46,[422,34],"Blood Pressure",[424,425,426,427],"Dextrose 20 % in 500 ML","Intralipid","Saline","Ascorbic acid",{"trials":429,"activeCount":101},[],{"trials":431,"activeCount":149,"soonestReadout":40},[432],{"nctId":38,"briefTitle":39,"status":228,"phases":433,"primaryCompletion":40,"completion":434,"start":435,"enrollment":9,"conditions":436,"interventions":437},[89,90],"2026-08","2019-10-17",[21],[41],{"trials":439,"activeCount":101},[],{"trials":441,"activeCount":101},[],{"trials":443,"activeCount":149,"soonestReadout":448},[444],{"nctId":445,"briefTitle":446,"status":138,"phases":447,"primaryCompletion":448,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":453},"NCT06626113","Transduction of Sympathetic Neural Activity in Human Obesity Without Hypertension",[],"2026-09-01","2027-09-01","2022-08-01",60,[18],[454],"ascorbic acid",{"intervention":237,"totalTrials":456,"cells":457},5,{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":459,"activeCount":101},[],{"trials":461,"activeCount":101},[],{"trials":463,"activeCount":356,"soonestReadout":140},[464,475,479,491,504],{"nctId":465,"briefTitle":466,"status":333,"phases":467,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":472,"interventions":473},"NCT00669162","Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer",[89,90],"2016-08","2017-04","2012-08",27,[31],[237,474],"Casodex and Zoladex",{"nctId":226,"briefTitle":227,"status":228,"phases":476,"primaryCompletion":140,"completion":230,"start":231,"enrollment":232,"conditions":477,"interventions":478},[90],[234,15],[236,237,238,239,217],{"nctId":480,"briefTitle":481,"status":138,"phases":482,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":488},"NCT07220135","Trial of Neoadjuvant THP vs TCHP for HER2-Amplified\u002FPositive Breast Cancer",[90],"2027-11-14","2031-05-14","2025-11-14",100,[15],[236,237,489,490],"Trastuzumab","Pertuzumab",{"nctId":492,"briefTitle":493,"status":127,"phases":494,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":501},"NCT00591149","Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer",[90],"2012-04","2007-06",16,[499,500],"Head and Neck Cancer","Carcinoma, Squamous",[502,237,503],"Oxaliplatin","Cetuximab",{"nctId":241,"briefTitle":242,"status":243,"phases":505,"primaryCompletion":245,"completion":246,"start":247,"enrollment":190,"conditions":506,"interventions":507},[90],[249],[236,237,217,251],{"trials":509,"activeCount":101},[],{"trials":511,"activeCount":101},[],{"trials":513,"activeCount":101},[],{"intervention":239,"totalTrials":515,"cells":516},4,{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":535,"PHASE3":569,"PHASE4":571,"NA":573},{"trials":518,"activeCount":101},[],{"trials":520,"activeCount":149,"soonestReadout":525},[521],{"nctId":522,"briefTitle":523,"status":138,"phases":524,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":529,"interventions":532},"NCT06879340","Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies",[89],"2030-03","2040-03","2025-03-31",54,[530,531],"B-Cell Non-Hodgkin Lymphoma","B-cell Acute Lymphoblastic Leukemia",[533,534,239],"DuoCAR20.19.22-D95","Fludarabine",{"trials":536,"activeCount":149,"soonestReadout":140},[537,541,555],{"nctId":226,"briefTitle":227,"status":228,"phases":538,"primaryCompletion":140,"completion":230,"start":231,"enrollment":232,"conditions":539,"interventions":540},[90],[234,15],[236,237,238,239,217],{"nctId":542,"briefTitle":543,"status":333,"phases":544,"primaryCompletion":545,"completion":545,"start":546,"enrollment":27,"conditions":547,"interventions":552},"NCT06151847","Lifileucel With Reduced Dose Fludarabine\u002FCyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma",[90],"2025-07-10","2023-12-21",[548,549,550,551],"Clinical Stage IV Cutaneous Melanoma AJCC v8","Metastatic Melanoma","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Unresectable Melanoma",[239,534,553,554],"Interleukin-2","Lifileucel",{"nctId":556,"briefTitle":557,"status":333,"phases":558,"primaryCompletion":559,"completion":560,"start":561,"enrollment":562,"conditions":563,"interventions":564},"NCT00944047","Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression",[90],"2014-05","2017-08","2009-07",32,[15],[565,566,238,567,568],"nab-paclitaxel","trastuzumab","cyclophosphamide","Growth Factor Support",{"trials":570,"activeCount":101},[],{"trials":572,"activeCount":101},[],{"trials":574,"activeCount":101},[],{"intervention":236,"totalTrials":97,"cells":576},{"EARLY_PHASE1":577,"PHASE1":579,"PHASE2":581,"PHASE3":595,"PHASE4":597,"NA":599},{"trials":578,"activeCount":101},[],{"trials":580,"activeCount":101},[],{"trials":582,"activeCount":356,"soonestReadout":140},[583,587,591],{"nctId":226,"briefTitle":227,"status":228,"phases":584,"primaryCompletion":140,"completion":230,"start":231,"enrollment":232,"conditions":585,"interventions":586},[90],[234,15],[236,237,238,239,217],{"nctId":480,"briefTitle":481,"status":138,"phases":588,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":589,"interventions":590},[90],[15],[236,237,489,490],{"nctId":241,"briefTitle":242,"status":243,"phases":592,"primaryCompletion":245,"completion":246,"start":247,"enrollment":190,"conditions":593,"interventions":594},[90],[249],[236,237,217,251],{"trials":596,"activeCount":101},[],{"trials":598,"activeCount":101},[],{"trials":600,"activeCount":101},[],{"intervention":426,"totalTrials":97,"cells":602},{"EARLY_PHASE1":603,"PHASE1":609,"PHASE2":611,"PHASE3":633,"PHASE4":635,"NA":637},{"trials":604,"activeCount":149,"soonestReadout":417},[605],{"nctId":414,"briefTitle":415,"status":138,"phases":606,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":607,"interventions":608},[88],[422,34],[424,425,426,427],{"trials":610,"activeCount":101},[],{"trials":612,"activeCount":149,"soonestReadout":417},[613,623],{"nctId":614,"briefTitle":615,"status":111,"phases":616,"primaryCompletion":617,"completion":617,"start":618,"enrollment":101,"conditions":619,"interventions":621},"NCT04635774","Post Operative Delirium Study",[89,90],"2023-11-14","2021-02-25",[620],"Delirium",[622,426],"Insulin",{"nctId":624,"briefTitle":625,"status":138,"phases":626,"primaryCompletion":417,"completion":418,"start":627,"enrollment":628,"conditions":629,"interventions":631},"NCT04715022","Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)",[89,90],"2021-06-17",23,[34,630],"Cardiovascular Diseases",[632,426],"Ascorbic acid solution",{"trials":634,"activeCount":101},[],{"trials":636,"activeCount":101},[],{"trials":638,"activeCount":101},[],{"intervention":81,"totalTrials":356,"cells":640},{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":652,"PHASE3":668,"PHASE4":670,"NA":672},{"trials":642,"activeCount":101},[],{"trials":644,"activeCount":149,"soonestReadout":60},[645],{"nctId":58,"briefTitle":59,"status":228,"phases":646,"primaryCompletion":60,"completion":140,"start":647,"enrollment":648,"conditions":649,"interventions":650},[89],"2022-03-28",18,[15],[61,651],"Sacituzumab govitecan",{"trials":653,"activeCount":149,"soonestReadout":80},[654],{"nctId":78,"briefTitle":79,"status":228,"phases":655,"primaryCompletion":80,"completion":656,"start":657,"enrollment":658,"conditions":659,"interventions":667},[90],"2026-11-01","2024-02-01",15,[660,661,662,663,664,665,666],"Locally Advanced Cholangiocarcinoma","Metastatic Cholangiocarcinoma","Recurrent Cholangiocarcinoma","Stage III Hilar Cholangiocarcinoma AJCC v8","Stage III Intrahepatic Cholangiocarcinoma AJCC v8","Stage IV Hilar Cholangiocarcinoma AJCC v8","Stage IV Intrahepatic Cholangiocarcinoma AJCC v8",[81],{"trials":669,"activeCount":101},[],{"trials":671,"activeCount":101},[],{"trials":673,"activeCount":101},[],{"intervention":675,"totalTrials":97,"cells":676},"Losartan",{"EARLY_PHASE1":677,"PHASE1":690,"PHASE2":702,"PHASE3":714,"PHASE4":716,"NA":718},{"trials":678,"activeCount":101},[679],{"nctId":680,"briefTitle":681,"status":333,"phases":682,"primaryCompletion":683,"completion":684,"start":685,"enrollment":686,"conditions":687,"interventions":689},"NCT03435939","Effect of Losartan in Cystic Fibrosis (CF)-NIH Grant #133240",[88],"2025-09-03","2026-03-31","2022-02-15",13,[688],"Cystic Fibrosis",[675],{"trials":691,"activeCount":101},[692],{"nctId":693,"briefTitle":694,"status":333,"phases":695,"primaryCompletion":696,"completion":697,"start":698,"enrollment":284,"conditions":699,"interventions":701},"NCT04335123","Study of Open Label Losartan in COVID-19",[89],"2020-06-21","2020-08-17","2020-04-04",[700],"COVID-19",[675],{"trials":703,"activeCount":149,"soonestReadout":708},[704],{"nctId":705,"briefTitle":706,"status":138,"phases":707,"primaryCompletion":708,"completion":709,"start":710,"enrollment":711,"conditions":712,"interventions":713},"NCT06364176","Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.",[90],"2027-05","2027-10","2024-06-03",42,[688],[675],{"trials":715,"activeCount":101},[],{"trials":717,"activeCount":101},[],{"trials":719,"activeCount":101},[],{"intervention":238,"totalTrials":356,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":723,"activeCount":101},[],{"trials":725,"activeCount":101},[],{"trials":727,"activeCount":149,"soonestReadout":140},[728,732],{"nctId":226,"briefTitle":227,"status":228,"phases":729,"primaryCompletion":140,"completion":230,"start":231,"enrollment":232,"conditions":730,"interventions":731},[90],[234,15],[236,237,238,239,217],{"nctId":556,"briefTitle":557,"status":333,"phases":733,"primaryCompletion":559,"completion":560,"start":561,"enrollment":562,"conditions":734,"interventions":735},[90],[15],[565,566,238,567,568],{"trials":737,"activeCount":101},[],{"trials":739,"activeCount":101},[],{"trials":741,"activeCount":101},[],{"intervention":743,"totalTrials":356,"cells":744},"Atezolizumab",{"EARLY_PHASE1":745,"PHASE1":747,"PHASE2":757,"PHASE3":771,"PHASE4":773,"NA":775},{"trials":746,"activeCount":101},[],{"trials":748,"activeCount":101},[749],{"nctId":750,"briefTitle":751,"status":111,"phases":752,"primaryCompletion":753,"completion":753,"start":753,"enrollment":101,"conditions":754,"interventions":756},"NCT06416436","Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients",[89],"2024-07-15",[755],"Solid Tumor",[743],{"trials":758,"activeCount":149,"soonestReadout":763},[759],{"nctId":760,"briefTitle":761,"status":138,"phases":762,"primaryCompletion":763,"completion":764,"start":765,"enrollment":766,"conditions":767,"interventions":770},"NCT04467723","Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC",[89,90],"2027-01-01","2027-08","2022-05-18",25,[768,769],"NSCLC Stage IV","NSCLC, Recurrent",[743],{"trials":772,"activeCount":101},[],{"trials":774,"activeCount":101},[],{"trials":776,"activeCount":101},[],{"intervention":489,"totalTrials":356,"cells":778},{"EARLY_PHASE1":779,"PHASE1":781,"PHASE2":783,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":780,"activeCount":101},[],{"trials":782,"activeCount":101},[],{"trials":784,"activeCount":149,"soonestReadout":483},[785,789],{"nctId":480,"briefTitle":481,"status":138,"phases":786,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":787,"interventions":788},[90],[15],[236,237,489,490],{"nctId":556,"briefTitle":557,"status":333,"phases":790,"primaryCompletion":559,"completion":560,"start":561,"enrollment":562,"conditions":791,"interventions":792},[90],[15],[565,566,238,567,568],{"trials":794,"activeCount":101},[],{"trials":796,"activeCount":101},[],{"trials":798,"activeCount":101},[],{"intervention":800,"totalTrials":149,"cells":801},"Intravenous ascorbic acid\u002Fvitamin C",{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":818,"PHASE4":820,"NA":822},{"trials":803,"activeCount":101},[],{"trials":805,"activeCount":101},[],{"trials":807,"activeCount":149,"soonestReadout":812},[808],{"nctId":809,"briefTitle":810,"status":138,"phases":811,"primaryCompletion":812,"completion":813,"start":814,"enrollment":815,"conditions":816,"interventions":817},"NCT06493370","Intravenous Ascorbate Plus Gemcitabine\u002FCarboplatin: A Novel and Cost-Effective Alternative With Evident Efficacy in Patients With Muscle Invasive Bladder Cancer",[90],"2028-12-01","2030-12-01","2025-01-16",48,[21],[800],{"trials":819,"activeCount":101},[],{"trials":821,"activeCount":101},[],{"trials":823,"activeCount":101},[],{"intervention":71,"totalTrials":149,"cells":825},{"EARLY_PHASE1":826,"PHASE1":828,"PHASE2":830,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":827,"activeCount":101},[],{"trials":829,"activeCount":101},[],{"trials":831,"activeCount":149,"soonestReadout":70},[832],{"nctId":68,"briefTitle":69,"status":833,"phases":834,"primaryCompletion":70,"completion":835,"start":836,"enrollment":837,"conditions":838,"interventions":842},"NOT_YET_RECRUITING",[90],"2026-10-23","2023-11-20",90,[839,840,841],"Stage IIC Prostate Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8",[71],{"trials":844,"activeCount":101},[],{"trials":846,"activeCount":101},[],{"trials":848,"activeCount":101},[],{"intervention":850,"totalTrials":149,"cells":851},"Bazedoxifene and Conjugated Estrogens",{"EARLY_PHASE1":852,"PHASE1":854,"PHASE2":856,"PHASE3":868,"PHASE4":870,"NA":872},{"trials":853,"activeCount":101},[],{"trials":855,"activeCount":101},[],{"trials":857,"activeCount":149,"soonestReadout":862},[858],{"nctId":859,"briefTitle":860,"status":228,"phases":861,"primaryCompletion":862,"completion":863,"start":864,"enrollment":190,"conditions":865,"interventions":867},"NCT04821141","Phase IIB Trial of Bazedoxifene Plus Conjugated Estrogens",[90],"2026-07-31","2027-07-31","2021-12-14",[866,15],"Risk Reduction",[850],{"trials":869,"activeCount":101},[],{"trials":871,"activeCount":101},[],{"trials":873,"activeCount":101},[],{"intervention":490,"totalTrials":149,"cells":875},{"EARLY_PHASE1":876,"PHASE1":878,"PHASE2":880,"PHASE3":886,"PHASE4":888,"NA":890},{"trials":877,"activeCount":101},[],{"trials":879,"activeCount":101},[],{"trials":881,"activeCount":149,"soonestReadout":483},[882],{"nctId":480,"briefTitle":481,"status":138,"phases":883,"primaryCompletion":483,"completion":484,"start":485,"enrollment":486,"conditions":884,"interventions":885},[90],[15],[236,237,489,490],{"trials":887,"activeCount":101},[],{"trials":889,"activeCount":101},[],{"trials":891,"activeCount":101},[],{"intervention":86,"totalTrials":149,"cells":893},{"EARLY_PHASE1":894,"PHASE1":896,"PHASE2":898,"PHASE3":908,"PHASE4":910,"NA":912},{"trials":895,"activeCount":101},[],{"trials":897,"activeCount":101},[],{"trials":899,"activeCount":149,"soonestReadout":85},[900],{"nctId":83,"briefTitle":84,"status":138,"phases":901,"primaryCompletion":85,"completion":902,"start":903,"enrollment":16,"conditions":904,"interventions":906},[89,90],"2027-01","2025-02",[905],"Pancreatic Cancer",[86,907],"NALIRIFOX",{"trials":909,"activeCount":101},[],{"trials":911,"activeCount":101},[],{"trials":913,"activeCount":101},[],{"intervention":907,"totalTrials":149,"cells":915},{"EARLY_PHASE1":916,"PHASE1":918,"PHASE2":920,"PHASE3":926,"PHASE4":928,"NA":930},{"trials":917,"activeCount":101},[],{"trials":919,"activeCount":101},[],{"trials":921,"activeCount":149,"soonestReadout":85},[922],{"nctId":83,"briefTitle":84,"status":138,"phases":923,"primaryCompletion":85,"completion":902,"start":903,"enrollment":16,"conditions":924,"interventions":925},[89,90],[905],[86,907],{"trials":927,"activeCount":101},[],{"trials":929,"activeCount":101},[],{"trials":931,"activeCount":101},[],{"intervention":933,"totalTrials":149,"cells":934},"Metformin Hydrochloride",{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":952,"PHASE4":954,"NA":956},{"trials":936,"activeCount":101},[],{"trials":938,"activeCount":101},[],{"trials":940,"activeCount":149,"soonestReadout":945},[941],{"nctId":942,"briefTitle":943,"status":138,"phases":944,"primaryCompletion":945,"completion":946,"start":947,"enrollment":948,"conditions":949,"interventions":951},"NCT04530383","Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function",[90],"2027-12-30","2028-07-15","2022-02-14",30,[950,688],"Cystic Fibrosis-related Diabetes",[933],{"trials":953,"activeCount":101},[],{"trials":955,"activeCount":101},[],{"trials":957,"activeCount":101},[],{"intervention":51,"totalTrials":149,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":964,"PHASE3":977,"PHASE4":979,"NA":981},{"trials":961,"activeCount":101},[],{"trials":963,"activeCount":101},[],{"trials":965,"activeCount":149,"soonestReadout":50},[966],{"nctId":48,"briefTitle":49,"status":228,"phases":967,"primaryCompletion":50,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":975},[90],"2025-04-30","2018-06-27",40,[972,973,974],"Gastro Esophageal Junction Cancer","Stomach Cancer","Adenocarcinoma",[51,976],"Adjuvant Treatment - mFOLFOX & Pembrolizumab",{"trials":978,"activeCount":101},[],{"trials":980,"activeCount":101},[],{"trials":982,"activeCount":101},[],{"intervention":976,"totalTrials":149,"cells":984},{"EARLY_PHASE1":985,"PHASE1":987,"PHASE2":989,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":986,"activeCount":101},[],{"trials":988,"activeCount":101},[],{"trials":990,"activeCount":149,"soonestReadout":50},[991],{"nctId":48,"briefTitle":49,"status":228,"phases":992,"primaryCompletion":50,"completion":968,"start":969,"enrollment":970,"conditions":993,"interventions":994},[90],[972,973,974],[51,976],{"trials":996,"activeCount":101},[],{"trials":998,"activeCount":101},[],{"trials":1000,"activeCount":101},[],{"intervention":76,"totalTrials":149,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1004,"activeCount":101},[],{"trials":1006,"activeCount":101},[],{"trials":1008,"activeCount":149,"soonestReadout":75},[1009],{"nctId":73,"briefTitle":74,"status":228,"phases":1010,"primaryCompletion":75,"completion":140,"start":1011,"enrollment":970,"conditions":1012,"interventions":1014},[89,90],"2022-03-22",[1013],"Advanced Biliary Tract Cancer",[76,1015],"Regorafenib",{"trials":1017,"activeCount":101},[],{"trials":1019,"activeCount":101},[],{"trials":1021,"activeCount":101},[],{"intervention":1015,"totalTrials":149,"cells":1023},{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":1025,"activeCount":101},[],{"trials":1027,"activeCount":101},[],{"trials":1029,"activeCount":149,"soonestReadout":75},[1030],{"nctId":73,"briefTitle":74,"status":228,"phases":1031,"primaryCompletion":75,"completion":140,"start":1011,"enrollment":970,"conditions":1032,"interventions":1033},[89,90],[1013],[76,1015],{"trials":1035,"activeCount":101},[],{"trials":1037,"activeCount":101},[],{"trials":1039,"activeCount":101},[],{"intervention":1041,"totalTrials":149,"cells":1042},"CaHMB",{"EARLY_PHASE1":1043,"PHASE1":1045,"PHASE2":1047,"PHASE3":1058,"PHASE4":1060,"NA":1062},{"trials":1044,"activeCount":101},[],{"trials":1046,"activeCount":101},[],{"trials":1048,"activeCount":149,"soonestReadout":230},[1049],{"nctId":1050,"briefTitle":1051,"status":138,"phases":1052,"primaryCompletion":230,"completion":1053,"start":1054,"enrollment":948,"conditions":1055,"interventions":1057},"NCT05869812","Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes",[90],"2029-12","2023-05-29",[1056],"Atrophy",[1041],{"trials":1059,"activeCount":101},[],{"trials":1061,"activeCount":101},[],{"trials":1063,"activeCount":101},[],{"intervention":632,"totalTrials":149,"cells":1065},{"EARLY_PHASE1":1066,"PHASE1":1068,"PHASE2":1070,"PHASE3":1076,"PHASE4":1078,"NA":1080},{"trials":1067,"activeCount":101},[],{"trials":1069,"activeCount":101},[],{"trials":1071,"activeCount":149,"soonestReadout":417},[1072],{"nctId":624,"briefTitle":625,"status":138,"phases":1073,"primaryCompletion":417,"completion":418,"start":627,"enrollment":628,"conditions":1074,"interventions":1075},[89,90],[34,630],[632,426],{"trials":1077,"activeCount":101},[],{"trials":1079,"activeCount":101},[],{"trials":1081,"activeCount":101},[],{"intervention":56,"totalTrials":149,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1085,"activeCount":101},[],{"trials":1087,"activeCount":101},[],{"trials":1089,"activeCount":149,"soonestReadout":55},[1090],{"nctId":53,"briefTitle":54,"status":228,"phases":1091,"primaryCompletion":55,"completion":1092,"start":1093,"enrollment":1094,"conditions":1095,"interventions":1097},[90],"2025-12","2022-12-15",24,[1096],"Pancreas Cancer",[56,1098,1099],"QS-21","Balstilimab",{"trials":1101,"activeCount":101},[],{"trials":1103,"activeCount":101},[],{"trials":1105,"activeCount":101},[],{"intervention":1098,"totalTrials":149,"cells":1107},{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1118,"PHASE4":1120,"NA":1122},{"trials":1109,"activeCount":101},[],{"trials":1111,"activeCount":101},[],{"trials":1113,"activeCount":149,"soonestReadout":55},[1114],{"nctId":53,"briefTitle":54,"status":228,"phases":1115,"primaryCompletion":55,"completion":1092,"start":1093,"enrollment":1094,"conditions":1116,"interventions":1117},[90],[1096],[56,1098,1099],{"trials":1119,"activeCount":101},[],{"trials":1121,"activeCount":101},[],{"trials":1123,"activeCount":101},[],{"intervention":1099,"totalTrials":149,"cells":1125},{"EARLY_PHASE1":1126,"PHASE1":1128,"PHASE2":1130,"PHASE3":1136,"PHASE4":1138,"NA":1140},{"trials":1127,"activeCount":101},[],{"trials":1129,"activeCount":101},[],{"trials":1131,"activeCount":149,"soonestReadout":55},[1132],{"nctId":53,"briefTitle":54,"status":228,"phases":1133,"primaryCompletion":55,"completion":1092,"start":1093,"enrollment":1094,"conditions":1134,"interventions":1135},[90],[1096],[56,1098,1099],{"trials":1137,"activeCount":101},[],{"trials":1139,"activeCount":101},[],{"trials":1141,"activeCount":101},[],{"intervention":66,"totalTrials":149,"cells":1143},{"EARLY_PHASE1":1144,"PHASE1":1146,"PHASE2":1148,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1145,"activeCount":101},[],{"trials":1147,"activeCount":101},[],{"trials":1149,"activeCount":149,"soonestReadout":65},[1150],{"nctId":63,"briefTitle":64,"status":228,"phases":1151,"primaryCompletion":65,"completion":1152,"start":1153,"enrollment":1154,"conditions":1155,"interventions":1158},[90],"2026-06-01","2023-06-30",28,[1156,1157,1096],"Pancreatic Ductal Adenocarcinoma","Pancreas Adenocarcinoma",[66],{"trials":1160,"activeCount":101},[],{"trials":1162,"activeCount":101},[],{"trials":1164,"activeCount":101},[],{"intervention":534,"totalTrials":356,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1169,"PHASE2":1175,"PHASE3":1181,"PHASE4":1183,"NA":1185},{"trials":1168,"activeCount":101},[],{"trials":1170,"activeCount":149,"soonestReadout":525},[1171],{"nctId":522,"briefTitle":523,"status":138,"phases":1172,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":1173,"interventions":1174},[89],[530,531],[533,534,239],{"trials":1176,"activeCount":101},[1177],{"nctId":542,"briefTitle":543,"status":333,"phases":1178,"primaryCompletion":545,"completion":545,"start":546,"enrollment":27,"conditions":1179,"interventions":1180},[90],[548,549,550,551],[239,534,553,554],{"trials":1182,"activeCount":101},[],{"trials":1184,"activeCount":101},[],{"trials":1186,"activeCount":101},[],{"intervention":1188,"totalTrials":149,"cells":1189},"Hydrochlorothiazide 12.5Mg Tab",{"EARLY_PHASE1":1190,"PHASE1":1192,"PHASE2":1206,"PHASE3":1208,"PHASE4":1210,"NA":1212},{"trials":1191,"activeCount":101},[],{"trials":1193,"activeCount":149,"soonestReadout":417},[1194],{"nctId":1195,"briefTitle":1196,"status":138,"phases":1197,"primaryCompletion":417,"completion":418,"start":1198,"enrollment":451,"conditions":1199,"interventions":1204},"NCT04934228","Mitigating the Pro-inflammatory Phenotype of Obesity",[89],"2021-07-01",[422,1200,18,1201,1202,1203],"Diabetes","Insulin Resistance","Diuretics Drug Reactions","Sympathetic Nerve Activity",[1188,1205],"Clonidine Pill",{"trials":1207,"activeCount":101},[],{"trials":1209,"activeCount":101},[],{"trials":1211,"activeCount":101},[],{"trials":1213,"activeCount":101},[],{"intervention":1205,"totalTrials":149,"cells":1215},{"EARLY_PHASE1":1216,"PHASE1":1218,"PHASE2":1224,"PHASE3":1226,"PHASE4":1228,"NA":1230},{"trials":1217,"activeCount":101},[],{"trials":1219,"activeCount":149,"soonestReadout":417},[1220],{"nctId":1195,"briefTitle":1196,"status":138,"phases":1221,"primaryCompletion":417,"completion":418,"start":1198,"enrollment":451,"conditions":1222,"interventions":1223},[89],[422,1200,18,1201,1202,1203],[1188,1205],{"trials":1225,"activeCount":101},[],{"trials":1227,"activeCount":101},[],{"trials":1229,"activeCount":101},[],{"trials":1231,"activeCount":101},[],{"intervention":1233,"totalTrials":149,"cells":1234},"EAGD T-cell",{"EARLY_PHASE1":1235,"PHASE1":1237,"PHASE2":1252,"PHASE3":1254,"PHASE4":1256,"NA":1258},{"trials":1236,"activeCount":101},[],{"trials":1238,"activeCount":149,"soonestReadout":902},[1239],{"nctId":1240,"briefTitle":1241,"status":138,"phases":1242,"primaryCompletion":902,"completion":1243,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1251},"NCT03533816","Expanded\u002FActivated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide",[89],"2028-01","2020-01-31",38,[1247,1248,1249,1250],"Acute Myeloid Leukemia","Chronic Myeloid Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndromes",[1233,1233],{"trials":1253,"activeCount":101},[],{"trials":1255,"activeCount":101},[],{"trials":1257,"activeCount":101},[],{"trials":1259,"activeCount":101},[],{"intervention":61,"totalTrials":149,"cells":1261},{"EARLY_PHASE1":1262,"PHASE1":1264,"PHASE2":1270,"PHASE3":1272,"PHASE4":1274,"NA":1276},{"trials":1263,"activeCount":101},[],{"trials":1265,"activeCount":149,"soonestReadout":60},[1266],{"nctId":58,"briefTitle":59,"status":228,"phases":1267,"primaryCompletion":60,"completion":140,"start":647,"enrollment":648,"conditions":1268,"interventions":1269},[89],[15],[61,651],{"trials":1271,"activeCount":101},[],{"trials":1273,"activeCount":101},[],{"trials":1275,"activeCount":101},[],{"trials":1277,"activeCount":101},[],{"intervention":533,"totalTrials":149,"cells":1279},{"EARLY_PHASE1":1280,"PHASE1":1282,"PHASE2":1288,"PHASE3":1290,"PHASE4":1292,"NA":1294},{"trials":1281,"activeCount":101},[],{"trials":1283,"activeCount":149,"soonestReadout":525},[1284],{"nctId":522,"briefTitle":523,"status":138,"phases":1285,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":1286,"interventions":1287},[89],[530,531],[533,534,239],{"trials":1289,"activeCount":101},[],{"trials":1291,"activeCount":101},[],{"trials":1293,"activeCount":101},[],{"trials":1295,"activeCount":101},[],{"intervention":46,"totalTrials":149,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1311,"PHASE3":1313,"PHASE4":1315,"NA":1317},{"trials":1299,"activeCount":101},[],{"trials":1301,"activeCount":149,"soonestReadout":45},[1302],{"nctId":43,"briefTitle":44,"status":228,"phases":1303,"primaryCompletion":45,"completion":1304,"start":1305,"enrollment":1306,"conditions":1307,"interventions":1309},[89],"2026-06-30","2022-09-14",10,[1308],"Barrett Oesophagitis With Dysplasia",[46,1310],"Itraconazole in solution form",{"trials":1312,"activeCount":101},[],{"trials":1314,"activeCount":101},[],{"trials":1316,"activeCount":101},[],{"trials":1318,"activeCount":101},[],{"intervention":1310,"totalTrials":149,"cells":1320},{"EARLY_PHASE1":1321,"PHASE1":1323,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1335},{"trials":1322,"activeCount":101},[],{"trials":1324,"activeCount":149,"soonestReadout":45},[1325],{"nctId":43,"briefTitle":44,"status":228,"phases":1326,"primaryCompletion":45,"completion":1304,"start":1305,"enrollment":1306,"conditions":1327,"interventions":1328},[89],[1308],[46,1310],{"trials":1330,"activeCount":101},[],{"trials":1332,"activeCount":101},[],{"trials":1334,"activeCount":101},[],{"trials":1336,"activeCount":101},[],{"intervention":1338,"totalTrials":149,"cells":1339},"Tagraxofusp",{"EARLY_PHASE1":1340,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1341,"activeCount":149,"soonestReadout":140},[1342],{"nctId":1343,"briefTitle":1344,"status":138,"phases":1345,"primaryCompletion":140,"completion":140,"start":1346,"enrollment":1347,"conditions":1348,"interventions":1350},"NCT06414681","Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or Declined",[88],"2025-08-25",20,[1349],"Myelofibrosis，MF",[1338,1351],"Pacritinib",{"trials":1353,"activeCount":101},[],{"trials":1355,"activeCount":101},[],{"trials":1357,"activeCount":101},[],{"trials":1359,"activeCount":101},[],{"trials":1361,"activeCount":101},[],{"intervention":1351,"totalTrials":149,"cells":1363},{"EARLY_PHASE1":1364,"PHASE1":1370,"PHASE2":1372,"PHASE3":1374,"PHASE4":1376,"NA":1378},{"trials":1365,"activeCount":149,"soonestReadout":140},[1366],{"nctId":1343,"briefTitle":1344,"status":138,"phases":1367,"primaryCompletion":140,"completion":140,"start":1346,"enrollment":1347,"conditions":1368,"interventions":1369},[88],[1349],[1338,1351],{"trials":1371,"activeCount":101},[],{"trials":1373,"activeCount":101},[],{"trials":1375,"activeCount":101},[],{"trials":1377,"activeCount":101},[],{"trials":1379,"activeCount":101},[],{"intervention":1381,"totalTrials":149,"cells":1382},"Hydrochlorothiazide 12.5mg",{"EARLY_PHASE1":1383,"PHASE1":1395,"PHASE2":1397,"PHASE3":1399,"PHASE4":1401,"NA":1403},{"trials":1384,"activeCount":149,"soonestReadout":140},[1385],{"nctId":1386,"briefTitle":1387,"status":228,"phases":1388,"primaryCompletion":140,"completion":399,"start":1389,"enrollment":1390,"conditions":1391,"interventions":1394},"NCT04676399","Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction",[88],"2022-02-08",36,[1392,34,1202,1393],"Chronic Pain","SCS",[1381],{"trials":1396,"activeCount":101},[],{"trials":1398,"activeCount":101},[],{"trials":1400,"activeCount":101},[],{"trials":1402,"activeCount":101},[],{"trials":1404,"activeCount":101},[],{"intervention":424,"totalTrials":149,"cells":1406},{"EARLY_PHASE1":1407,"PHASE1":1413,"PHASE2":1415,"PHASE3":1417,"PHASE4":1419,"NA":1421},{"trials":1408,"activeCount":149,"soonestReadout":417},[1409],{"nctId":414,"briefTitle":415,"status":138,"phases":1410,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":1411,"interventions":1412},[88],[422,34],[424,425,426,427],{"trials":1414,"activeCount":101},[],{"trials":1416,"activeCount":101},[],{"trials":1418,"activeCount":101},[],{"trials":1420,"activeCount":101},[],{"trials":1422,"activeCount":101},[],{"intervention":425,"totalTrials":149,"cells":1424},{"EARLY_PHASE1":1425,"PHASE1":1431,"PHASE2":1433,"PHASE3":1435,"PHASE4":1437,"NA":1439},{"trials":1426,"activeCount":149,"soonestReadout":417},[1427],{"nctId":414,"briefTitle":415,"status":138,"phases":1428,"primaryCompletion":417,"completion":418,"start":419,"enrollment":420,"conditions":1429,"interventions":1430},[88],[422,34],[424,425,426,427],{"trials":1432,"activeCount":101},[],{"trials":1434,"activeCount":101},[],{"trials":1436,"activeCount":101},[],{"trials":1438,"activeCount":101},[],{"trials":1440,"activeCount":101},[],{"intervention":1442,"totalTrials":456,"cells":1443},"Hyperpolarized Xe129",{"EARLY_PHASE1":1444,"PHASE1":1446,"PHASE2":1458,"PHASE3":1469,"PHASE4":1471,"NA":1473},{"trials":1445,"activeCount":101},[],{"trials":1447,"activeCount":101},[1448],{"nctId":1449,"briefTitle":1450,"status":333,"phases":1451,"primaryCompletion":1452,"completion":1453,"start":1454,"enrollment":711,"conditions":1455,"interventions":1457},"NCT04659707","Hyperpolarized 129Xe MRI of Survivors of COVID-19",[89],"2025-01-01","2025-05-01","2021-02-22",[1456],"Covid19",[1442],{"trials":1459,"activeCount":101},[1460],{"nctId":1461,"briefTitle":1462,"status":111,"phases":1463,"primaryCompletion":450,"completion":450,"start":1464,"enrollment":101,"conditions":1465,"interventions":1468},"NCT04677426","129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study",[90],"2022-05-01",[1466,1467],"Idiopathic Pulmonary Fibrosis","Hypersensitivity Pneumonitis",[1442],{"trials":1470,"activeCount":101},[],{"trials":1472,"activeCount":101},[],{"trials":1474,"activeCount":149,"soonestReadout":1496},[1475,1483,1492],{"nctId":1476,"briefTitle":1477,"status":333,"phases":1478,"primaryCompletion":527,"completion":1479,"start":1464,"enrollment":766,"conditions":1480,"interventions":1482},"NCT05204355","MRI for Screening and Monitoring Scleroderma ILD",[],"2025-10-31",[1481],"Scleroderma",[1442],{"nctId":1484,"briefTitle":1485,"status":333,"phases":1486,"primaryCompletion":527,"completion":1487,"start":1488,"enrollment":1306,"conditions":1489,"interventions":1491},"NCT05339386","Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension",[],"2025-07-31","2022-08-29",[1490],"Pulmonary Arterial Hypertension",[1442],{"nctId":1493,"briefTitle":1494,"status":138,"phases":1495,"primaryCompletion":1496,"completion":1496,"start":1497,"enrollment":1498,"conditions":1499,"interventions":1501},"NCT05766384","Hyperpolarized 129Xe MRI Lung Health Cohort",[],"2027-03-31","2023-11-30",260,[1500],"Healthy",[1442],{"intervention":1503,"totalTrials":149,"cells":1504},"Hyperpolarized 129 Xenon",{"EARLY_PHASE1":1505,"PHASE1":1507,"PHASE2":1509,"PHASE3":1511,"PHASE4":1513,"NA":1515},{"trials":1506,"activeCount":101},[],{"trials":1508,"activeCount":101},[],{"trials":1510,"activeCount":101},[],{"trials":1512,"activeCount":101},[],{"trials":1514,"activeCount":101},[],{"trials":1516,"activeCount":149,"soonestReadout":140},[1517],{"nctId":1518,"briefTitle":1519,"status":138,"phases":1520,"primaryCompletion":140,"completion":140,"start":65,"enrollment":456,"conditions":1521,"interventions":1523},"NCT06985225","Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma",[],[1522],"Severe Asthma",[1503],{"intervention":1525,"totalTrials":97,"cells":1526},"Nicotine Replacement Therapy",{"EARLY_PHASE1":1527,"PHASE1":1529,"PHASE2":1531,"PHASE3":1533,"PHASE4":1547,"NA":1570},{"trials":1528,"activeCount":101},[],{"trials":1530,"activeCount":101},[],{"trials":1532,"activeCount":101},[],{"trials":1534,"activeCount":101},[1535],{"nctId":1536,"briefTitle":1537,"status":333,"phases":1538,"primaryCompletion":1539,"completion":1539,"start":559,"enrollment":1540,"conditions":1541,"interventions":1545},"NCT02148445","Smoking Cessation Versus Long-term Nicotine Replacement Among High-risk Smokers",[91],"2016-12",398,[1542,1543,1544],"Smoking","Pulmonary Disease, Chronic Obstructive","Tobacco Use Disorder",[1546],"Nicotine replacement therapy",{"trials":1548,"activeCount":101},[1549,1559],{"nctId":1550,"briefTitle":1551,"status":333,"phases":1552,"primaryCompletion":1553,"completion":1554,"start":1555,"enrollment":1556,"conditions":1557,"interventions":1558},"NCT02244918","Informing Tobacco Treatment Guidelines for African American Non-Daily Smokers",[92],"2017-11-01","2018-03-15","2015-05",278,[26],[1525],{"nctId":1560,"briefTitle":1561,"status":333,"phases":1562,"primaryCompletion":1563,"completion":1564,"start":1565,"enrollment":1566,"conditions":1567,"interventions":1569},"NCT02721082","Changing the Default for Tobacco Treatment",[92],"2020-07-27","2020-12-09","2016-09-01",1000,[1568],"Tobacco Use Cessation",[1525,1525],{"trials":1571,"activeCount":101},[],{"intervention":1573,"totalTrials":356,"cells":1574},"Lipitor 20Mg",{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1579,"PHASE3":1581,"PHASE4":1583,"NA":1605},{"trials":1576,"activeCount":101},[],{"trials":1578,"activeCount":101},[],{"trials":1580,"activeCount":101},[],{"trials":1582,"activeCount":101},[],{"trials":1584,"activeCount":101},[1585,1595],{"nctId":1586,"briefTitle":1587,"status":333,"phases":1588,"primaryCompletion":1589,"completion":1589,"start":1590,"enrollment":1591,"conditions":1592,"interventions":1593},"NCT03360916","Impact of Statin Therapy on Adaptations to Aerobic Exercise",[92],"2024-06-05","2018-02-01",52,[630],[1573,1594],"Lipitor 80Mg",{"nctId":1596,"briefTitle":1597,"status":333,"phases":1598,"primaryCompletion":1599,"completion":1599,"start":1600,"enrollment":1601,"conditions":1602,"interventions":1604},"NCT03351998","Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity",[92],"2023-07-07","2018-02-22",68,[1603],"Mitochondrial Diseases",[1573,1594],{"trials":1606,"activeCount":101},[],{"intervention":1594,"totalTrials":356,"cells":1608},{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1615,"PHASE4":1617,"NA":1627},{"trials":1610,"activeCount":101},[],{"trials":1612,"activeCount":101},[],{"trials":1614,"activeCount":101},[],{"trials":1616,"activeCount":101},[],{"trials":1618,"activeCount":101},[1619,1623],{"nctId":1586,"briefTitle":1587,"status":333,"phases":1620,"primaryCompletion":1589,"completion":1589,"start":1590,"enrollment":1591,"conditions":1621,"interventions":1622},[92],[630],[1573,1594],{"nctId":1596,"briefTitle":1597,"status":333,"phases":1624,"primaryCompletion":1599,"completion":1599,"start":1600,"enrollment":1601,"conditions":1625,"interventions":1626},[92],[1603],[1573,1594],{"trials":1628,"activeCount":101},[],{"intervention":1630,"totalTrials":356,"cells":1631},"Gabapentin",{"EARLY_PHASE1":1632,"PHASE1":1634,"PHASE2":1636,"PHASE3":1638,"PHASE4":1648,"NA":1665},{"trials":1633,"activeCount":101},[],{"trials":1635,"activeCount":101},[],{"trials":1637,"activeCount":101},[],{"trials":1639,"activeCount":101},[1640],{"nctId":1641,"briefTitle":1642,"status":111,"phases":1643,"primaryCompletion":1644,"completion":1644,"start":561,"enrollment":101,"conditions":1645,"interventions":1647},"NCT00934193","Does Peri-Operative Gabapentin Reduce Chronic Post-Thoracotomy Pain?",[91],"2011-06",[1646],"Post-thoracotomy Pain",[1630],{"trials":1649,"activeCount":101},[1650],{"nctId":1651,"briefTitle":1652,"status":333,"phases":1653,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":948,"conditions":1657,"interventions":1659},"NCT04246697","Multimodal Pain Study in Free Flap Patients",[92],"2021-06-01","2023-05-01","2019-11-01",[499,1658],"Analgesia",[1660,1661,1662,1630,1663,1664],"Tylenol","Oxycodone","Morphine","toradol","Bupivacaine",{"trials":1666,"activeCount":101},[],{"intervention":1664,"totalTrials":356,"cells":1668},{"EARLY_PHASE1":1669,"PHASE1":1671,"PHASE2":1685,"PHASE3":1687,"PHASE4":1689,"NA":1695},{"trials":1670,"activeCount":101},[],{"trials":1672,"activeCount":101},[1673],{"nctId":1674,"briefTitle":1675,"status":243,"phases":1676,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":1679,"conditions":1680,"interventions":1683},"NCT04585867","Liposomal Bupivacaine vs Bupivacaine for Pain Control After Sternotomy",[89],"2023-10-10","2017-10-11",80,[1681,1682],"Pain Management","Sternotomy",[1684,1664],"Exparel",{"trials":1686,"activeCount":101},[],{"trials":1688,"activeCount":101},[],{"trials":1690,"activeCount":101},[1691],{"nctId":1651,"briefTitle":1652,"status":333,"phases":1692,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":948,"conditions":1693,"interventions":1694},[92],[499,1658],[1660,1661,1662,1630,1663,1664],{"trials":1696,"activeCount":101},[],{"intervention":1684,"totalTrials":356,"cells":1698},{"EARLY_PHASE1":1699,"PHASE1":1701,"PHASE2":1707,"PHASE3":1709,"PHASE4":1711,"NA":1725},{"trials":1700,"activeCount":101},[],{"trials":1702,"activeCount":101},[1703],{"nctId":1674,"briefTitle":1675,"status":243,"phases":1704,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":1679,"conditions":1705,"interventions":1706},[89],[1681,1682],[1684,1664],{"trials":1708,"activeCount":101},[],{"trials":1710,"activeCount":101},[],{"trials":1712,"activeCount":101},[1713],{"nctId":1714,"briefTitle":1715,"status":333,"phases":1716,"primaryCompletion":1717,"completion":1717,"start":1718,"enrollment":1719,"conditions":1720,"interventions":1722},"NCT02128646","Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair",[92],"2017-01","2014-04",19,[1721],"Pain",[1723,1724],"EXPAREL","Ketorolac",{"trials":1726,"activeCount":101},[],{"intervention":1728,"totalTrials":149,"cells":1729},"Hyoscyamine",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1750},{"trials":1731,"activeCount":101},[],{"trials":1733,"activeCount":101},[],{"trials":1735,"activeCount":101},[],{"trials":1737,"activeCount":101},[],{"trials":1739,"activeCount":101},[1740],{"nctId":1741,"briefTitle":1742,"status":127,"phases":1743,"primaryCompletion":1744,"completion":1744,"start":1745,"enrollment":456,"conditions":1746,"interventions":1748},"NCT03750656","Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation",[92],"2020-08-31","2018-11-12",[1747],"Lower Urinary Tract Symptoms",[1728,1749],"Tamsulosin",{"trials":1751,"activeCount":101},[],{"intervention":1749,"totalTrials":149,"cells":1753},{"EARLY_PHASE1":1754,"PHASE1":1756,"PHASE2":1758,"PHASE3":1760,"PHASE4":1762,"NA":1768},{"trials":1755,"activeCount":101},[],{"trials":1757,"activeCount":101},[],{"trials":1759,"activeCount":101},[],{"trials":1761,"activeCount":101},[],{"trials":1763,"activeCount":101},[1764],{"nctId":1741,"briefTitle":1742,"status":127,"phases":1765,"primaryCompletion":1744,"completion":1744,"start":1745,"enrollment":456,"conditions":1766,"interventions":1767},[92],[1747],[1728,1749],{"trials":1769,"activeCount":101},[],{"intervention":1771,"totalTrials":149,"cells":1772},"Collagenase Santyl",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1794},{"trials":1774,"activeCount":101},[],{"trials":1776,"activeCount":101},[],{"trials":1778,"activeCount":101},[],{"trials":1780,"activeCount":101},[],{"trials":1782,"activeCount":101},[1783],{"nctId":1784,"briefTitle":1785,"status":127,"phases":1786,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1347,"conditions":1790,"interventions":1792},"NCT02673229","Comparison of Collagenase With Antibiotic Ointment of Minor Partial Thickness Burns",[92],"2018-12-27","2020-03-30","2013-09-30",[1791],"Burn, Partial Thickness",[1771,1793],"Bacitracin",{"trials":1795,"activeCount":101},[],{"intervention":1793,"totalTrials":149,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1812},{"trials":1799,"activeCount":101},[],{"trials":1801,"activeCount":101},[],{"trials":1803,"activeCount":101},[],{"trials":1805,"activeCount":101},[],{"trials":1807,"activeCount":101},[1808],{"nctId":1784,"briefTitle":1785,"status":127,"phases":1809,"primaryCompletion":1787,"completion":1788,"start":1789,"enrollment":1347,"conditions":1810,"interventions":1811},[92],[1791],[1771,1793],{"trials":1813,"activeCount":101},[],{"intervention":1815,"totalTrials":149,"cells":1816},"Zilretta",{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1823,"PHASE4":1825,"NA":1837},{"trials":1818,"activeCount":101},[],{"trials":1820,"activeCount":101},[],{"trials":1822,"activeCount":101},[],{"trials":1824,"activeCount":101},[],{"trials":1826,"activeCount":101},[1827],{"nctId":1828,"briefTitle":1829,"status":333,"phases":1830,"primaryCompletion":1831,"completion":1831,"start":1832,"enrollment":1833,"conditions":1834,"interventions":1836},"NCT03895840","The Effect of Intra-articular Bilateral Knee Injections of Zilretta on Performance Measures in Adults With Knee OA",[92],"2021-05-03","2018-03-19",70,[1835],"Knee Osteoarthritis",[1815],{"trials":1838,"activeCount":101},[],{"intervention":1840,"totalTrials":149,"cells":1841},"Lidocaine Hydrochloride",{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1848,"PHASE4":1850,"NA":1865},{"trials":1843,"activeCount":101},[],{"trials":1845,"activeCount":101},[],{"trials":1847,"activeCount":101},[],{"trials":1849,"activeCount":101},[],{"trials":1851,"activeCount":101},[1852],{"nctId":1853,"briefTitle":1854,"status":333,"phases":1855,"primaryCompletion":1856,"completion":1857,"start":1858,"enrollment":1859,"conditions":1860,"interventions":1862},"NCT03854344","Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain",[92],"2025-08-06","2025-10-27","2019-03-18",74,[1861,144],"Pain, Postoperative",[1840,1863,1864],"Liposomal bupivacaine","Bupivacaine Hydrochloride",{"trials":1866,"activeCount":101},[],{"intervention":1863,"totalTrials":149,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1875,"PHASE4":1877,"NA":1883},{"trials":1870,"activeCount":101},[],{"trials":1872,"activeCount":101},[],{"trials":1874,"activeCount":101},[],{"trials":1876,"activeCount":101},[],{"trials":1878,"activeCount":101},[1879],{"nctId":1853,"briefTitle":1854,"status":333,"phases":1880,"primaryCompletion":1856,"completion":1857,"start":1858,"enrollment":1859,"conditions":1881,"interventions":1882},[92],[1861,144],[1840,1863,1864],{"trials":1884,"activeCount":101},[],{"intervention":1864,"totalTrials":149,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1891,"PHASE3":1893,"PHASE4":1895,"NA":1901},{"trials":1888,"activeCount":101},[],{"trials":1890,"activeCount":101},[],{"trials":1892,"activeCount":101},[],{"trials":1894,"activeCount":101},[],{"trials":1896,"activeCount":101},[1897],{"nctId":1853,"briefTitle":1854,"status":333,"phases":1898,"primaryCompletion":1856,"completion":1857,"start":1858,"enrollment":1859,"conditions":1899,"interventions":1900},[92],[1861,144],[1840,1863,1864],{"trials":1902,"activeCount":101},[],{"intervention":1904,"totalTrials":149,"cells":1905},"Desmopressin",{"EARLY_PHASE1":1906,"PHASE1":1908,"PHASE2":1910,"PHASE3":1912,"PHASE4":1914,"NA":1925},{"trials":1907,"activeCount":101},[],{"trials":1909,"activeCount":101},[],{"trials":1911,"activeCount":101},[],{"trials":1913,"activeCount":101},[],{"trials":1915,"activeCount":101},[1916],{"nctId":1917,"briefTitle":1918,"status":111,"phases":1919,"primaryCompletion":1920,"completion":1920,"start":1921,"enrollment":101,"conditions":1922,"interventions":1924},"NCT03676361","To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors",[92],"2019-04-26","2018-08-29",[1923],"Kidney Damage",[1904],{"trials":1926,"activeCount":101},[],{"intervention":1660,"totalTrials":149,"cells":1928},{"EARLY_PHASE1":1929,"PHASE1":1931,"PHASE2":1933,"PHASE3":1935,"PHASE4":1937,"NA":1943},{"trials":1930,"activeCount":101},[],{"trials":1932,"activeCount":101},[],{"trials":1934,"activeCount":101},[],{"trials":1936,"activeCount":101},[],{"trials":1938,"activeCount":101},[1939],{"nctId":1651,"briefTitle":1652,"status":333,"phases":1940,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":948,"conditions":1941,"interventions":1942},[92],[499,1658],[1660,1661,1662,1630,1663,1664],{"trials":1944,"activeCount":101},[],{"intervention":1661,"totalTrials":149,"cells":1946},{"EARLY_PHASE1":1947,"PHASE1":1949,"PHASE2":1951,"PHASE3":1953,"PHASE4":1955,"NA":1961},{"trials":1948,"activeCount":101},[],{"trials":1950,"activeCount":101},[],{"trials":1952,"activeCount":101},[],{"trials":1954,"activeCount":101},[],{"trials":1956,"activeCount":101},[1957],{"nctId":1651,"briefTitle":1652,"status":333,"phases":1958,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":948,"conditions":1959,"interventions":1960},[92],[499,1658],[1660,1661,1662,1630,1663,1664],{"trials":1962,"activeCount":101},[],{"intervention":1662,"totalTrials":149,"cells":1964},{"EARLY_PHASE1":1965,"PHASE1":1967,"PHASE2":1969,"PHASE3":1971,"PHASE4":1973,"NA":1979},{"trials":1966,"activeCount":101},[],{"trials":1968,"activeCount":101},[],{"trials":1970,"activeCount":101},[],{"trials":1972,"activeCount":101},[],{"trials":1974,"activeCount":101},[1975],{"nctId":1651,"briefTitle":1652,"status":333,"phases":1976,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":948,"conditions":1977,"interventions":1978},[92],[499,1658],[1660,1661,1662,1630,1663,1664],{"trials":1980,"activeCount":101},[],{"intervention":1663,"totalTrials":149,"cells":1982},{"EARLY_PHASE1":1983,"PHASE1":1985,"PHASE2":1987,"PHASE3":1989,"PHASE4":1991,"NA":1997},{"trials":1984,"activeCount":101},[],{"trials":1986,"activeCount":101},[],{"trials":1988,"activeCount":101},[],{"trials":1990,"activeCount":101},[],{"trials":1992,"activeCount":101},[1993],{"nctId":1651,"briefTitle":1652,"status":333,"phases":1994,"primaryCompletion":1654,"completion":1655,"start":1656,"enrollment":948,"conditions":1995,"interventions":1996},[92],[499,1658],[1660,1661,1662,1630,1663,1664],{"trials":1998,"activeCount":101},[],{"intervention":2000,"totalTrials":149,"cells":2001},"Lansoprazole",{"EARLY_PHASE1":2002,"PHASE1":2004,"PHASE2":2006,"PHASE3":2008,"PHASE4":2010,"NA":2020},{"trials":2003,"activeCount":101},[],{"trials":2005,"activeCount":101},[],{"trials":2007,"activeCount":101},[],{"trials":2009,"activeCount":101},[],{"trials":2011,"activeCount":101},[2012],{"nctId":2013,"briefTitle":2014,"status":127,"phases":2015,"primaryCompletion":561,"completion":561,"start":2016,"enrollment":32,"conditions":2017,"interventions":2019},"NCT00637416","Dietary Control Alone Versus Dietary Control Plus Use of Proton Pump Inhibitors to Treat Pediatric Hoarseness",[92],"2008-03",[2018],"Dysphonia",[2000],{"trials":2021,"activeCount":101},[],{"intervention":2023,"totalTrials":149,"cells":2024},"bezlotoxumab",{"EARLY_PHASE1":2025,"PHASE1":2027,"PHASE2":2029,"PHASE3":2031,"PHASE4":2033,"NA":2045},{"trials":2026,"activeCount":101},[],{"trials":2028,"activeCount":101},[],{"trials":2030,"activeCount":101},[],{"trials":2032,"activeCount":101},[],{"trials":2034,"activeCount":101},[2035],{"nctId":2036,"briefTitle":2037,"status":333,"phases":2038,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":515,"conditions":2041,"interventions":2043},"NCT03880539","Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection",[92],"2021-11-18","2019-06-25",[2042],"Clostridium Difficile Infection Recurrence",[2023,2044],"Vancomycin",{"trials":2046,"activeCount":101},[],{"intervention":2044,"totalTrials":149,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2053,"PHASE3":2055,"PHASE4":2057,"NA":2063},{"trials":2050,"activeCount":101},[],{"trials":2052,"activeCount":101},[],{"trials":2054,"activeCount":101},[],{"trials":2056,"activeCount":101},[],{"trials":2058,"activeCount":101},[2059],{"nctId":2036,"briefTitle":2037,"status":333,"phases":2060,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":515,"conditions":2061,"interventions":2062},[92],[2042],[2023,2044],{"trials":2064,"activeCount":101},[],{"intervention":2066,"totalTrials":149,"cells":2067},"Megestrol Acetate",{"EARLY_PHASE1":2068,"PHASE1":2070,"PHASE2":2072,"PHASE3":2074,"PHASE4":2076,"NA":2088},{"trials":2069,"activeCount":101},[],{"trials":2071,"activeCount":101},[],{"trials":2073,"activeCount":101},[],{"trials":2075,"activeCount":101},[],{"trials":2077,"activeCount":101},[2078],{"nctId":2079,"briefTitle":2080,"status":333,"phases":2081,"primaryCompletion":2082,"completion":2082,"start":2083,"enrollment":1833,"conditions":2084,"interventions":2087},"NCT03815019","iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children",[92],"2025-03-19","2019-08-15",[2085,2086],"Feeding Behavior","Feeding Disorder of Infancy or Early Childhood",[2066],{"trials":2089,"activeCount":101},[],{"intervention":2091,"totalTrials":149,"cells":2092},"Ketamine",{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2097,"PHASE3":2099,"PHASE4":2101,"NA":2112},{"trials":2094,"activeCount":101},[],{"trials":2096,"activeCount":101},[],{"trials":2098,"activeCount":101},[],{"trials":2100,"activeCount":101},[],{"trials":2102,"activeCount":101},[2103],{"nctId":2104,"briefTitle":2105,"status":111,"phases":2106,"primaryCompletion":2107,"completion":2107,"start":2108,"enrollment":101,"conditions":2109,"interventions":2110},"NCT03095222","Exploring the Safety and Efficacy of Low-dose Ketamine Infusions for Pain Control in Acute Burn Injury",[92],"2018-05-24","2017-04-01",[1721],[2091,2111],"Opioids",{"trials":2113,"activeCount":101},[],{"intervention":2111,"totalTrials":149,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2122,"PHASE4":2124,"NA":2130},{"trials":2117,"activeCount":101},[],{"trials":2119,"activeCount":101},[],{"trials":2121,"activeCount":101},[],{"trials":2123,"activeCount":101},[],{"trials":2125,"activeCount":101},[2126],{"nctId":2104,"briefTitle":2105,"status":111,"phases":2127,"primaryCompletion":2107,"completion":2107,"start":2108,"enrollment":101,"conditions":2128,"interventions":2129},[92],[1721],[2091,2111],{"trials":2131,"activeCount":101},[],{"intervention":2133,"totalTrials":149,"cells":2134},"Nortriptyline",{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2139,"PHASE3":2141,"PHASE4":2143,"NA":2158},{"trials":2136,"activeCount":101},[],{"trials":2138,"activeCount":101},[],{"trials":2140,"activeCount":101},[],{"trials":2142,"activeCount":101},[],{"trials":2144,"activeCount":101},[2145],{"nctId":2146,"briefTitle":2147,"status":333,"phases":2148,"primaryCompletion":2149,"completion":2149,"start":2150,"enrollment":2151,"conditions":2152,"interventions":2154},"NCT02260388","Patient Assisted Intervention for Neuropathy: Comparison of Treatment in Real Life Situations",[92],"2017-09","2014-10",402,[2153],"Cryptogenic Sensory Polyneuropathy",[2133,2155,2156,2157],"Duloxetine","Pregabalin","Mexiletine",{"trials":2159,"activeCount":101},[],{"intervention":2155,"totalTrials":149,"cells":2161},{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2166,"PHASE3":2168,"PHASE4":2170,"NA":2176},{"trials":2163,"activeCount":101},[],{"trials":2165,"activeCount":101},[],{"trials":2167,"activeCount":101},[],{"trials":2169,"activeCount":101},[],{"trials":2171,"activeCount":101},[2172],{"nctId":2146,"briefTitle":2147,"status":333,"phases":2173,"primaryCompletion":2149,"completion":2149,"start":2150,"enrollment":2151,"conditions":2174,"interventions":2175},[92],[2153],[2133,2155,2156,2157],{"trials":2177,"activeCount":101},[],{"intervention":2156,"totalTrials":149,"cells":2179},{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2188,"NA":2194},{"trials":2181,"activeCount":101},[],{"trials":2183,"activeCount":101},[],{"trials":2185,"activeCount":101},[],{"trials":2187,"activeCount":101},[],{"trials":2189,"activeCount":101},[2190],{"nctId":2146,"briefTitle":2147,"status":333,"phases":2191,"primaryCompletion":2149,"completion":2149,"start":2150,"enrollment":2151,"conditions":2192,"interventions":2193},[92],[2153],[2133,2155,2156,2157],{"trials":2195,"activeCount":101},[],{"intervention":2157,"totalTrials":149,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2200,"PHASE2":2202,"PHASE3":2204,"PHASE4":2206,"NA":2212},{"trials":2199,"activeCount":101},[],{"trials":2201,"activeCount":101},[],{"trials":2203,"activeCount":101},[],{"trials":2205,"activeCount":101},[],{"trials":2207,"activeCount":101},[2208],{"nctId":2146,"briefTitle":2147,"status":333,"phases":2209,"primaryCompletion":2149,"completion":2149,"start":2150,"enrollment":2151,"conditions":2210,"interventions":2211},[92],[2153],[2133,2155,2156,2157],{"trials":2213,"activeCount":101},[],{"intervention":1724,"totalTrials":149,"cells":2215},{"EARLY_PHASE1":2216,"PHASE1":2218,"PHASE2":2220,"PHASE3":2222,"PHASE4":2224,"NA":2230},{"trials":2217,"activeCount":101},[],{"trials":2219,"activeCount":101},[],{"trials":2221,"activeCount":101},[],{"trials":2223,"activeCount":101},[],{"trials":2225,"activeCount":101},[2226],{"nctId":1714,"briefTitle":1715,"status":333,"phases":2227,"primaryCompletion":1717,"completion":1717,"start":1718,"enrollment":1719,"conditions":2228,"interventions":2229},[92],[1721],[1723,1724],{"trials":2231,"activeCount":101},[],{"intervention":2233,"totalTrials":149,"cells":2234},"Pitavastin 4mg",{"EARLY_PHASE1":2235,"PHASE1":2237,"PHASE2":2239,"PHASE3":2241,"PHASE4":2243,"NA":2258},{"trials":2236,"activeCount":101},[],{"trials":2238,"activeCount":101},[],{"trials":2240,"activeCount":101},[],{"trials":2242,"activeCount":101},[],{"trials":2244,"activeCount":101},[2245],{"nctId":2246,"briefTitle":2247,"status":333,"phases":2248,"primaryCompletion":2249,"completion":2250,"start":2251,"enrollment":2252,"conditions":2253,"interventions":2255},"NCT01660191","A Study Comparing CoQ10 Levels While Taking 3 Different Statins",[92],"2013-08","2013-10","2011-12",134,[2254],"Hypercholesterolemia",[2233,2256,2257],"Atorvastatin 20mg","Rosuvastatin 5mg",{"trials":2259,"activeCount":101},[],{"intervention":2256,"totalTrials":149,"cells":2261},{"EARLY_PHASE1":2262,"PHASE1":2264,"PHASE2":2266,"PHASE3":2268,"PHASE4":2270,"NA":2276},{"trials":2263,"activeCount":101},[],{"trials":2265,"activeCount":101},[],{"trials":2267,"activeCount":101},[],{"trials":2269,"activeCount":101},[],{"trials":2271,"activeCount":101},[2272],{"nctId":2246,"briefTitle":2247,"status":333,"phases":2273,"primaryCompletion":2249,"completion":2250,"start":2251,"enrollment":2252,"conditions":2274,"interventions":2275},[92],[2254],[2233,2256,2257],{"trials":2277,"activeCount":101},[],{"intervention":2257,"totalTrials":149,"cells":2279},{"EARLY_PHASE1":2280,"PHASE1":2282,"PHASE2":2284,"PHASE3":2286,"PHASE4":2288,"NA":2294},{"trials":2281,"activeCount":101},[],{"trials":2283,"activeCount":101},[],{"trials":2285,"activeCount":101},[],{"trials":2287,"activeCount":101},[],{"trials":2289,"activeCount":101},[2290],{"nctId":2246,"briefTitle":2247,"status":333,"phases":2291,"primaryCompletion":2249,"completion":2250,"start":2251,"enrollment":2252,"conditions":2292,"interventions":2293},[92],[2254],[2233,2256,2257],{"trials":2295,"activeCount":101},[],{"intervention":2297,"totalTrials":356,"cells":2298},"Oxaloacetate",{"EARLY_PHASE1":2299,"PHASE1":2301,"PHASE2":2311,"PHASE3":2313,"PHASE4":2324,"NA":2326},{"trials":2300,"activeCount":101},[],{"trials":2302,"activeCount":101},[2303],{"nctId":2304,"briefTitle":2305,"status":111,"phases":2306,"primaryCompletion":434,"completion":140,"start":2307,"enrollment":101,"conditions":2308,"interventions":2310},"NCT04965987","Oxaloacetate in Myasthenia Gravis",[89],"2025-08",[2309],"Myasthenia Gravis",[2297],{"trials":2312,"activeCount":101},[],{"trials":2314,"activeCount":101},[2315],{"nctId":2316,"briefTitle":2317,"status":333,"phases":2318,"primaryCompletion":2150,"completion":2150,"start":2319,"enrollment":2320,"conditions":2321,"interventions":2323},"NCT01741701","A Pilot Study of Oxaloacetate in Subjects With Treated PD",[90,91],"2012-12",33,[2322],"Parkinson's Disease",[2297],{"trials":2325,"activeCount":101},[],{"trials":2327,"activeCount":101},[],{"intervention":340,"totalTrials":149,"cells":2329},{"EARLY_PHASE1":2330,"PHASE1":2332,"PHASE2":2334,"PHASE3":2336,"PHASE4":2342,"NA":2344},{"trials":2331,"activeCount":101},[],{"trials":2333,"activeCount":101},[],{"trials":2335,"activeCount":101},[],{"trials":2337,"activeCount":101},[2338],{"nctId":331,"briefTitle":332,"status":333,"phases":2339,"primaryCompletion":335,"completion":336,"start":115,"enrollment":337,"conditions":2340,"interventions":2341},[91],[26],[340,341,310],{"trials":2343,"activeCount":101},[],{"trials":2345,"activeCount":101},[],{"intervention":121,"totalTrials":149,"cells":2347},{"EARLY_PHASE1":2348,"PHASE1":2350,"PHASE2":2352,"PHASE3":2354,"PHASE4":2360,"NA":2362},{"trials":2349,"activeCount":101},[],{"trials":2351,"activeCount":101},[],{"trials":2353,"activeCount":101},[],{"trials":2355,"activeCount":101},[2356],{"nctId":109,"briefTitle":110,"status":111,"phases":2357,"primaryCompletion":113,"completion":114,"start":115,"enrollment":101,"conditions":2358,"interventions":2359},[91],[117,118,119],[96,121],{"trials":2361,"activeCount":101},[],{"trials":2363,"activeCount":101},[],{"intervention":2365,"totalTrials":149,"cells":2366},"Docosahexaenoic acid - 800mg\u002Fday",{"EARLY_PHASE1":2367,"PHASE1":2369,"PHASE2":2371,"PHASE3":2373,"PHASE4":2386,"NA":2388},{"trials":2368,"activeCount":101},[],{"trials":2370,"activeCount":101},[],{"trials":2372,"activeCount":101},[],{"trials":2374,"activeCount":101},[2375],{"nctId":2376,"briefTitle":2377,"status":333,"phases":2378,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2381,"conditions":2382,"interventions":2384},"NCT02626299","Assessment of DHA On Reducing Early Preterm Birth",[91],"2020-10-05","2016-06-08",1100,[2383],"Preterm Birth",[2365,2385],"Docosahexaenoic acid - 200mg\u002Fday",{"trials":2387,"activeCount":101},[],{"trials":2389,"activeCount":101},[],{"intervention":2385,"totalTrials":149,"cells":2391},{"EARLY_PHASE1":2392,"PHASE1":2394,"PHASE2":2396,"PHASE3":2398,"PHASE4":2404,"NA":2406},{"trials":2393,"activeCount":101},[],{"trials":2395,"activeCount":101},[],{"trials":2397,"activeCount":101},[],{"trials":2399,"activeCount":101},[2400],{"nctId":2376,"briefTitle":2377,"status":333,"phases":2401,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":2381,"conditions":2402,"interventions":2403},[91],[2383],[2365,2385],{"trials":2405,"activeCount":101},[],{"trials":2407,"activeCount":101},[],{"intervention":2409,"totalTrials":149,"cells":2410},"Sugammadex",{"EARLY_PHASE1":2411,"PHASE1":2413,"PHASE2":2415,"PHASE3":2417,"PHASE4":2429,"NA":2431},{"trials":2412,"activeCount":101},[],{"trials":2414,"activeCount":101},[],{"trials":2416,"activeCount":101},[],{"trials":2418,"activeCount":101},[2419],{"nctId":2420,"briefTitle":2421,"status":333,"phases":2422,"primaryCompletion":2423,"completion":2423,"start":1554,"enrollment":2424,"conditions":2425,"interventions":2426},"NCT03513406","Comparison of Reversal of Neuromuscular Blockade With Sugammadex Versus Neostigmine Plus Glycopyrolate in Patients Undergoing Burn Surgery",[91],"2023-03-07",7,[144],[2409,2427,2428],"Neostigmine","Glycopyrrolate",{"trials":2430,"activeCount":101},[],{"trials":2432,"activeCount":101},[],{"intervention":2427,"totalTrials":149,"cells":2434},{"EARLY_PHASE1":2435,"PHASE1":2437,"PHASE2":2439,"PHASE3":2441,"PHASE4":2447,"NA":2449},{"trials":2436,"activeCount":101},[],{"trials":2438,"activeCount":101},[],{"trials":2440,"activeCount":101},[],{"trials":2442,"activeCount":101},[2443],{"nctId":2420,"briefTitle":2421,"status":333,"phases":2444,"primaryCompletion":2423,"completion":2423,"start":1554,"enrollment":2424,"conditions":2445,"interventions":2446},[91],[144],[2409,2427,2428],{"trials":2448,"activeCount":101},[],{"trials":2450,"activeCount":101},[],{"intervention":2428,"totalTrials":149,"cells":2452},{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2457,"PHASE3":2459,"PHASE4":2465,"NA":2467},{"trials":2454,"activeCount":101},[],{"trials":2456,"activeCount":101},[],{"trials":2458,"activeCount":101},[],{"trials":2460,"activeCount":101},[2461],{"nctId":2420,"briefTitle":2421,"status":333,"phases":2462,"primaryCompletion":2423,"completion":2423,"start":1554,"enrollment":2424,"conditions":2463,"interventions":2464},[91],[144],[2409,2427,2428],{"trials":2466,"activeCount":101},[],{"trials":2468,"activeCount":101},[],{"intervention":2470,"totalTrials":97,"cells":2471},"Rituximab",{"EARLY_PHASE1":2472,"PHASE1":2484,"PHASE2":2486,"PHASE3":2506,"PHASE4":2508,"NA":2510},{"trials":2473,"activeCount":101},[2474],{"nctId":2475,"briefTitle":2476,"status":333,"phases":2477,"primaryCompletion":1718,"completion":2478,"start":2479,"enrollment":19,"conditions":2480,"interventions":2482},"NCT01022021","Peripheral Blood Stem Cell (PBSC) Mobilization in Patients With Relapsed Lymphoma Treated With Bendamustine",[88],"2015-08","2010-01",[2481],"Lymphoma",[2470,2483],"Bendamustine",{"trials":2485,"activeCount":101},[],{"trials":2487,"activeCount":101},[2488,2497],{"nctId":2489,"briefTitle":2490,"status":111,"phases":2491,"primaryCompletion":2492,"completion":2492,"start":2493,"enrollment":101,"conditions":2494,"interventions":2496},"NCT04480450","Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy",[90],"2025-09","2025-07",[2495],"Chronic Inflammatory Demyelinating Polyneuropathy",[2470],{"nctId":2498,"briefTitle":2499,"status":333,"phases":2500,"primaryCompletion":2501,"completion":2501,"start":2502,"enrollment":16,"conditions":2503,"interventions":2505},"NCT00856245","Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma",[90],"2015-07","2009-02",[2504],"Non-Hodgkins Lymphoma",[2470],{"trials":2507,"activeCount":101},[],{"trials":2509,"activeCount":101},[],{"trials":2511,"activeCount":101},[],{"intervention":2513,"totalTrials":356,"cells":2514},"Dexamethasone",{"EARLY_PHASE1":2515,"PHASE1":2517,"PHASE2":2519,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2516,"activeCount":101},[],{"trials":2518,"activeCount":101},[],{"trials":2520,"activeCount":101},[2521,2532],{"nctId":2522,"briefTitle":2523,"status":333,"phases":2524,"primaryCompletion":2525,"completion":561,"start":2526,"enrollment":766,"conditions":2527,"interventions":2529},"NCT00222105","A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life",[90],"2009-04","2002-11",[2528],"Multiple Myeloma",[2530,2531,2513],"Doxil","Thalidomide",{"nctId":2533,"briefTitle":2534,"status":333,"phases":2535,"primaryCompletion":2479,"completion":2479,"start":2536,"enrollment":1347,"conditions":2537,"interventions":2540},"NCT00600353","Multi-day Doses in Prevention of Nausea and Emesis",[90],"2007-10",[2538,2539],"Myeloma, Plasma-Cell","Lymphoma, Malignant",[2541,2542,2513],"Palonosetron","Aprepitant",{"trials":2544,"activeCount":101},[],{"trials":2546,"activeCount":101},[],{"trials":2548,"activeCount":101},[],{"intervention":2550,"totalTrials":356,"cells":2551},"Azacitidine",{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2566,"PHASE3":2577,"PHASE4":2579,"NA":2581},{"trials":2553,"activeCount":101},[],{"trials":2555,"activeCount":101},[2556],{"nctId":2557,"briefTitle":2558,"status":127,"phases":2559,"primaryCompletion":2560,"completion":2560,"start":2561,"enrollment":149,"conditions":2562,"interventions":2564},"NCT00443261","Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[89],"2008-06","2007-02",[2563],"Squamous Cell Carcinoma",[2550,2565],"Cisplatin",{"trials":2567,"activeCount":101},[2568],{"nctId":2569,"briefTitle":2570,"status":127,"phases":2571,"primaryCompletion":2572,"completion":2572,"start":347,"enrollment":27,"conditions":2573,"interventions":2575},"NCT00934440","A Study to Evaluate the Effectiveness of 5-Azacitidine and Bevacizumab in Advanced Renal Cell Carcinoma",[89,90],"2015-11",[2574],"Renal Cell Carcinoma",[2576,2550],"Bevacizumab",{"trials":2578,"activeCount":101},[],{"trials":2580,"activeCount":101},[],{"trials":2582,"activeCount":101},[],{"intervention":2530,"totalTrials":149,"cells":2584},{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2589,"PHASE3":2595,"PHASE4":2597,"NA":2599},{"trials":2586,"activeCount":101},[],{"trials":2588,"activeCount":101},[],{"trials":2590,"activeCount":101},[2591],{"nctId":2522,"briefTitle":2523,"status":333,"phases":2592,"primaryCompletion":2525,"completion":561,"start":2526,"enrollment":766,"conditions":2593,"interventions":2594},[90],[2528],[2530,2531,2513],{"trials":2596,"activeCount":101},[],{"trials":2598,"activeCount":101},[],{"trials":2600,"activeCount":101},[],{"intervention":2531,"totalTrials":149,"cells":2602},{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2613,"PHASE4":2615,"NA":2617},{"trials":2604,"activeCount":101},[],{"trials":2606,"activeCount":101},[],{"trials":2608,"activeCount":101},[2609],{"nctId":2522,"briefTitle":2523,"status":333,"phases":2610,"primaryCompletion":2525,"completion":561,"start":2526,"enrollment":766,"conditions":2611,"interventions":2612},[90],[2528],[2530,2531,2513],{"trials":2614,"activeCount":101},[],{"trials":2616,"activeCount":101},[],{"trials":2618,"activeCount":101},[],{"intervention":289,"totalTrials":149,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2622,"activeCount":101},[],{"trials":2624,"activeCount":101},[],{"trials":2626,"activeCount":101},[2627],{"nctId":279,"briefTitle":280,"status":243,"phases":2628,"primaryCompletion":282,"completion":55,"start":283,"enrollment":284,"conditions":2629,"interventions":2630},[89,90],[286,287],[289,290,265],{"trials":2632,"activeCount":101},[],{"trials":2634,"activeCount":101},[],{"trials":2636,"activeCount":101},[],{"intervention":290,"totalTrials":149,"cells":2638},{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2640,"activeCount":101},[],{"trials":2642,"activeCount":101},[],{"trials":2644,"activeCount":101},[2645],{"nctId":279,"briefTitle":280,"status":243,"phases":2646,"primaryCompletion":282,"completion":55,"start":283,"enrollment":284,"conditions":2647,"interventions":2648},[89,90],[286,287],[289,290,265],{"trials":2650,"activeCount":101},[],{"trials":2652,"activeCount":101},[],{"trials":2654,"activeCount":101},[],{"intervention":2656,"totalTrials":149,"cells":2657},"acolbifene hydrochloride",{"EARLY_PHASE1":2658,"PHASE1":2660,"PHASE2":2662,"PHASE3":2670,"PHASE4":2672,"NA":2674},{"trials":2659,"activeCount":101},[],{"trials":2661,"activeCount":101},[],{"trials":2663,"activeCount":101},[2664],{"nctId":2665,"briefTitle":2666,"status":333,"phases":2667,"primaryCompletion":346,"completion":346,"start":2502,"enrollment":766,"conditions":2668,"interventions":2669},"NCT00853996","Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer",[90],[15],[2656],{"trials":2671,"activeCount":101},[],{"trials":2673,"activeCount":101},[],{"trials":2675,"activeCount":101},[],{"intervention":474,"totalTrials":149,"cells":2677},{"EARLY_PHASE1":2678,"PHASE1":2680,"PHASE2":2682,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2679,"activeCount":101},[],{"trials":2681,"activeCount":101},[],{"trials":2683,"activeCount":101},[2684],{"nctId":465,"briefTitle":466,"status":333,"phases":2685,"primaryCompletion":468,"completion":469,"start":470,"enrollment":471,"conditions":2686,"interventions":2687},[89,90],[31],[237,474],{"trials":2689,"activeCount":101},[],{"trials":2691,"activeCount":101},[],{"trials":2693,"activeCount":101},[],{"intervention":2695,"totalTrials":149,"cells":2696},"Fulvestrant",{"EARLY_PHASE1":2697,"PHASE1":2699,"PHASE2":2701,"PHASE3":2714,"PHASE4":2716,"NA":2718},{"trials":2698,"activeCount":101},[],{"trials":2700,"activeCount":101},[],{"trials":2702,"activeCount":101},[2703],{"nctId":2704,"briefTitle":2705,"status":333,"phases":2706,"primaryCompletion":2707,"completion":2708,"start":2709,"enrollment":711,"conditions":2710,"interventions":2712},"NCT00921115","Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.",[90],"2015-04","2023-03-20","2009-05",[2711],"Invasive Breast Cancer",[2695,2713],"Anastrazole",{"trials":2715,"activeCount":101},[],{"trials":2717,"activeCount":101},[],{"trials":2719,"activeCount":101},[],{"intervention":2713,"totalTrials":149,"cells":2721},{"EARLY_PHASE1":2722,"PHASE1":2724,"PHASE2":2726,"PHASE3":2732,"PHASE4":2734,"NA":2736},{"trials":2723,"activeCount":101},[],{"trials":2725,"activeCount":101},[],{"trials":2727,"activeCount":101},[2728],{"nctId":2704,"briefTitle":2705,"status":333,"phases":2729,"primaryCompletion":2707,"completion":2708,"start":2709,"enrollment":711,"conditions":2730,"interventions":2731},[90],[2711],[2695,2713],{"trials":2733,"activeCount":101},[],{"trials":2735,"activeCount":101},[],{"trials":2737,"activeCount":101},[],{"intervention":2739,"totalTrials":149,"cells":2740},"Fentanyl Citrate",{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2745,"PHASE3":2759,"PHASE4":2761,"NA":2763},{"trials":2742,"activeCount":101},[],{"trials":2744,"activeCount":101},[],{"trials":2746,"activeCount":101},[2747],{"nctId":2748,"briefTitle":2749,"status":243,"phases":2750,"primaryCompletion":2751,"completion":2752,"start":2753,"enrollment":1679,"conditions":2754,"interventions":2756},"NCT06017141","Inhalational or Intravenous Anesthesia During Surgery for Patients With Colon Cancer, VIVA Study",[90],"2025-05-22","2026-05-22","2023-05-22",[2755],"Colon Adenocarcinoma",[2739,2757,2758],"Propofol","Sevoflurane",{"trials":2760,"activeCount":101},[],{"trials":2762,"activeCount":101},[],{"trials":2764,"activeCount":101},[],{"intervention":2757,"totalTrials":149,"cells":2766},{"EARLY_PHASE1":2767,"PHASE1":2769,"PHASE2":2771,"PHASE3":2777,"PHASE4":2779,"NA":2781},{"trials":2768,"activeCount":101},[],{"trials":2770,"activeCount":101},[],{"trials":2772,"activeCount":101},[2773],{"nctId":2748,"briefTitle":2749,"status":243,"phases":2774,"primaryCompletion":2751,"completion":2752,"start":2753,"enrollment":1679,"conditions":2775,"interventions":2776},[90],[2755],[2739,2757,2758],{"trials":2778,"activeCount":101},[],{"trials":2780,"activeCount":101},[],{"trials":2782,"activeCount":101},[],{"intervention":2758,"totalTrials":149,"cells":2784},{"EARLY_PHASE1":2785,"PHASE1":2787,"PHASE2":2789,"PHASE3":2795,"PHASE4":2797,"NA":2799},{"trials":2786,"activeCount":101},[],{"trials":2788,"activeCount":101},[],{"trials":2790,"activeCount":101},[2791],{"nctId":2748,"briefTitle":2749,"status":243,"phases":2792,"primaryCompletion":2751,"completion":2752,"start":2753,"enrollment":1679,"conditions":2793,"interventions":2794},[90],[2755],[2739,2757,2758],{"trials":2796,"activeCount":101},[],{"trials":2798,"activeCount":101},[],{"trials":2800,"activeCount":101},[],{"intervention":2802,"totalTrials":149,"cells":2803},"Niraparib Treatment",{"EARLY_PHASE1":2804,"PHASE1":2806,"PHASE2":2808,"PHASE3":2819,"PHASE4":2821,"NA":2823},{"trials":2805,"activeCount":101},[],{"trials":2807,"activeCount":101},[],{"trials":2809,"activeCount":101},[2810],{"nctId":2811,"briefTitle":2812,"status":243,"phases":2813,"primaryCompletion":2814,"completion":2815,"start":2816,"enrollment":648,"conditions":2817,"interventions":2818},"NCT03553004","Niraparib in Metastatic Pancreatic Cancer After Previous Chemotherapy (NIRA-PANC): a Phase 2 Trial",[90],"2023-04-25","2025-02-01","2019-01-22",[905],[2802],{"trials":2820,"activeCount":101},[],{"trials":2822,"activeCount":101},[],{"trials":2824,"activeCount":101},[],{"intervention":553,"totalTrials":149,"cells":2826},{"EARLY_PHASE1":2827,"PHASE1":2829,"PHASE2":2831,"PHASE3":2837,"PHASE4":2839,"NA":2841},{"trials":2828,"activeCount":101},[],{"trials":2830,"activeCount":101},[],{"trials":2832,"activeCount":101},[2833],{"nctId":542,"briefTitle":543,"status":333,"phases":2834,"primaryCompletion":545,"completion":545,"start":546,"enrollment":27,"conditions":2835,"interventions":2836},[90],[548,549,550,551],[239,534,553,554],{"trials":2838,"activeCount":101},[],{"trials":2840,"activeCount":101},[],{"trials":2842,"activeCount":101},[],{"intervention":554,"totalTrials":149,"cells":2844},{"EARLY_PHASE1":2845,"PHASE1":2847,"PHASE2":2849,"PHASE3":2855,"PHASE4":2857,"NA":2859},{"trials":2846,"activeCount":101},[],{"trials":2848,"activeCount":101},[],{"trials":2850,"activeCount":101},[2851],{"nctId":542,"briefTitle":543,"status":333,"phases":2852,"primaryCompletion":545,"completion":545,"start":546,"enrollment":27,"conditions":2853,"interventions":2854},[90],[548,549,550,551],[239,534,553,554],{"trials":2856,"activeCount":101},[],{"trials":2858,"activeCount":101},[],{"trials":2860,"activeCount":101},[],{"intervention":2862,"totalTrials":149,"cells":2863},"Pyridoxamine",{"EARLY_PHASE1":2864,"PHASE1":2866,"PHASE2":2868,"PHASE3":2878,"PHASE4":2880,"NA":2882},{"trials":2865,"activeCount":101},[],{"trials":2867,"activeCount":101},[],{"trials":2869,"activeCount":101},[2870],{"nctId":2871,"briefTitle":2872,"status":111,"phases":2873,"start":2874,"enrollment":101,"conditions":2875,"interventions":2877},"NCT00490113","A Trial of Pyridoxamine to Lower Urine Oxalate in Subjects With Stone Disease or Hyperoxaluria",[90],"2007-01",[2876],"Kidney Stones",[2862],{"trials":2879,"activeCount":101},[],{"trials":2881,"activeCount":101},[],{"trials":2883,"activeCount":101},[],{"intervention":2885,"totalTrials":149,"cells":2886},"Esomeprazole",{"EARLY_PHASE1":2887,"PHASE1":2889,"PHASE2":2891,"PHASE3":2903,"PHASE4":2905,"NA":2907},{"trials":2888,"activeCount":101},[],{"trials":2890,"activeCount":101},[],{"trials":2892,"activeCount":101},[2893],{"nctId":2894,"briefTitle":2895,"status":333,"phases":2896,"primaryCompletion":2897,"completion":2897,"start":2898,"enrollment":2899,"conditions":2900,"interventions":2902},"NCT00222131","Inhibition of Gastric Acid is the Key to Satisfactory Relief of Symptoms With Esomeprazole in NUD Patients",[90],"2008-01","2003-10",73,[2901],"Indigestion",[2885],{"trials":2904,"activeCount":101},[],{"trials":2906,"activeCount":101},[],{"trials":2908,"activeCount":101},[],{"intervention":2910,"totalTrials":149,"cells":2911},"Palbociclib 75mg",{"EARLY_PHASE1":2912,"PHASE1":2914,"PHASE2":2916,"PHASE3":2934,"PHASE4":2936,"NA":2938},{"trials":2913,"activeCount":101},[],{"trials":2915,"activeCount":101},[],{"trials":2917,"activeCount":101},[2918],{"nctId":2919,"briefTitle":2920,"status":127,"phases":2921,"primaryCompletion":2922,"completion":2923,"start":2924,"enrollment":97,"conditions":2925,"interventions":2928},"NCT03709082","Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer",[89,90],"2020-03-12","2021-02-03","2018-10-15",[2926,2927],"HER2-positive Breast Cancer","Breast Cancer Metastatic",[2910,2929,2930,2931,2932,2933],"Letrozole 2.5mg","T-DM1","Palbociclib 100mg","Palbociclib 125mg","Palbociclib",{"trials":2935,"activeCount":101},[],{"trials":2937,"activeCount":101},[],{"trials":2939,"activeCount":101},[],{"intervention":2929,"totalTrials":149,"cells":2941},{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2952,"PHASE4":2954,"NA":2956},{"trials":2943,"activeCount":101},[],{"trials":2945,"activeCount":101},[],{"trials":2947,"activeCount":101},[2948],{"nctId":2919,"briefTitle":2920,"status":127,"phases":2949,"primaryCompletion":2922,"completion":2923,"start":2924,"enrollment":97,"conditions":2950,"interventions":2951},[89,90],[2926,2927],[2910,2929,2930,2931,2932,2933],{"trials":2953,"activeCount":101},[],{"trials":2955,"activeCount":101},[],{"trials":2957,"activeCount":101},[],{"intervention":2930,"totalTrials":149,"cells":2959},{"EARLY_PHASE1":2960,"PHASE1":2962,"PHASE2":2964,"PHASE3":2970,"PHASE4":2972,"NA":2974},{"trials":2961,"activeCount":101},[],{"trials":2963,"activeCount":101},[],{"trials":2965,"activeCount":101},[2966],{"nctId":2919,"briefTitle":2920,"status":127,"phases":2967,"primaryCompletion":2922,"completion":2923,"start":2924,"enrollment":97,"conditions":2968,"interventions":2969},[89,90],[2926,2927],[2910,2929,2930,2931,2932,2933],{"trials":2971,"activeCount":101},[],{"trials":2973,"activeCount":101},[],{"trials":2975,"activeCount":101},[],{"intervention":2931,"totalTrials":149,"cells":2977},{"EARLY_PHASE1":2978,"PHASE1":2980,"PHASE2":2982,"PHASE3":2988,"PHASE4":2990,"NA":2992},{"trials":2979,"activeCount":101},[],{"trials":2981,"activeCount":101},[],{"trials":2983,"activeCount":101},[2984],{"nctId":2919,"briefTitle":2920,"status":127,"phases":2985,"primaryCompletion":2922,"completion":2923,"start":2924,"enrollment":97,"conditions":2986,"interventions":2987},[89,90],[2926,2927],[2910,2929,2930,2931,2932,2933],{"trials":2989,"activeCount":101},[],{"trials":2991,"activeCount":101},[],{"trials":2993,"activeCount":101},[],{"intervention":2932,"totalTrials":149,"cells":2995},{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3006,"PHASE4":3008,"NA":3010},{"trials":2997,"activeCount":101},[],{"trials":2999,"activeCount":101},[],{"trials":3001,"activeCount":101},[3002],{"nctId":2919,"briefTitle":2920,"status":127,"phases":3003,"primaryCompletion":2922,"completion":2923,"start":2924,"enrollment":97,"conditions":3004,"interventions":3005},[89,90],[2926,2927],[2910,2929,2930,2931,2932,2933],{"trials":3007,"activeCount":101},[],{"trials":3009,"activeCount":101},[],{"trials":3011,"activeCount":101},[],{"intervention":2933,"totalTrials":149,"cells":3013},{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3018,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3015,"activeCount":101},[],{"trials":3017,"activeCount":101},[],{"trials":3019,"activeCount":101},[3020],{"nctId":2919,"briefTitle":2920,"status":127,"phases":3021,"primaryCompletion":2922,"completion":2923,"start":2924,"enrollment":97,"conditions":3022,"interventions":3023},[89,90],[2926,2927],[2910,2929,2930,2931,2932,2933],{"trials":3025,"activeCount":101},[],{"trials":3027,"activeCount":101},[],{"trials":3029,"activeCount":101},[],{"intervention":622,"totalTrials":149,"cells":3031},{"EARLY_PHASE1":3032,"PHASE1":3034,"PHASE2":3036,"PHASE3":3042,"PHASE4":3044,"NA":3046},{"trials":3033,"activeCount":101},[],{"trials":3035,"activeCount":101},[],{"trials":3037,"activeCount":101},[3038],{"nctId":614,"briefTitle":615,"status":111,"phases":3039,"primaryCompletion":617,"completion":617,"start":618,"enrollment":101,"conditions":3040,"interventions":3041},[89,90],[620],[622,426],{"trials":3043,"activeCount":101},[],{"trials":3045,"activeCount":101},[],{"trials":3047,"activeCount":101},[],{"intervention":3049,"totalTrials":149,"cells":3050},"lapatinib",{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3055,"PHASE3":3066,"PHASE4":3068,"NA":3070},{"trials":3052,"activeCount":101},[],{"trials":3054,"activeCount":101},[],{"trials":3056,"activeCount":101},[3057],{"nctId":3058,"briefTitle":3059,"status":127,"phases":3060,"primaryCompletion":2572,"completion":3061,"start":3062,"enrollment":2320,"conditions":3063,"interventions":3065},"NCT00759642","Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy",[90],"2018-08-20","2009-03",[3064],"Metastatic Breast Cancer",[3049],{"trials":3067,"activeCount":101},[],{"trials":3069,"activeCount":101},[],{"trials":3071,"activeCount":101},[],{"intervention":3073,"totalTrials":149,"cells":3074},"sorafenib",{"EARLY_PHASE1":3075,"PHASE1":3077,"PHASE2":3079,"PHASE3":3088,"PHASE4":3090,"NA":3092},{"trials":3076,"activeCount":101},[],{"trials":3078,"activeCount":101},[],{"trials":3080,"activeCount":101},[3081],{"nctId":3082,"briefTitle":3083,"status":333,"phases":3084,"primaryCompletion":2707,"completion":2707,"start":2560,"enrollment":766,"conditions":3085,"interventions":3087},"NCT01189370","Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer",[90],[3086],"Renal Cell Cancer",[3073],{"trials":3089,"activeCount":101},[],{"trials":3091,"activeCount":101},[],{"trials":3093,"activeCount":101},[],{"intervention":3095,"totalTrials":149,"cells":3096},"Methotrexate",{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3101,"PHASE3":3111,"PHASE4":3113,"NA":3115},{"trials":3098,"activeCount":101},[],{"trials":3100,"activeCount":101},[],{"trials":3102,"activeCount":101},[3103],{"nctId":3104,"briefTitle":3105,"status":333,"phases":3106,"primaryCompletion":3107,"completion":3107,"start":2525,"enrollment":3108,"conditions":3109,"interventions":3110},"NCT00814138","Efficacy of Methotrexate in Myasthenia Gravis",[90],"2014-01",50,[2309],[3095],{"trials":3112,"activeCount":101},[],{"trials":3114,"activeCount":101},[],{"trials":3116,"activeCount":101},[],{"intervention":3118,"totalTrials":149,"cells":3119},"Memantine",{"EARLY_PHASE1":3120,"PHASE1":3122,"PHASE2":3124,"PHASE3":3137,"PHASE4":3139,"NA":3141},{"trials":3121,"activeCount":101},[],{"trials":3123,"activeCount":101},[],{"trials":3125,"activeCount":101},[3126],{"nctId":3127,"briefTitle":3128,"status":333,"phases":3129,"primaryCompletion":3130,"completion":3130,"start":3131,"enrollment":3132,"conditions":3133,"interventions":3136},"NCT02118727","Therapy in Amyotrophic Lateral Sclerosis (TAME)",[90],"2021-07-22","2018-11-07",89,[3134,3135],"Amyotrophic Lateral Sclerosis","Frontal Temporal Dementia",[3118],{"trials":3138,"activeCount":101},[],{"trials":3140,"activeCount":101},[],{"trials":3142,"activeCount":101},[],{"intervention":3144,"totalTrials":149,"cells":3145},"celecoxib",{"EARLY_PHASE1":3146,"PHASE1":3148,"PHASE2":3150,"PHASE3":3162,"PHASE4":3164,"NA":3166},{"trials":3147,"activeCount":101},[],{"trials":3149,"activeCount":101},[],{"trials":3151,"activeCount":101},[3152],{"nctId":3153,"briefTitle":3154,"status":333,"phases":3155,"primaryCompletion":3156,"completion":3157,"start":3158,"enrollment":3159,"conditions":3160,"interventions":3161},"NCT00056082","Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women",[90],"2008-07","2013-07","2003-01",110,[15],[3144],{"trials":3163,"activeCount":101},[],{"trials":3165,"activeCount":101},[],{"trials":3167,"activeCount":101},[],{"intervention":3169,"totalTrials":149,"cells":3170},"Brentuximab Vedotin",{"EARLY_PHASE1":3171,"PHASE1":3173,"PHASE2":3175,"PHASE3":3187,"PHASE4":3189,"NA":3191},{"trials":3172,"activeCount":101},[],{"trials":3174,"activeCount":101},[],{"trials":3176,"activeCount":101},[3177],{"nctId":3178,"briefTitle":3179,"status":111,"phases":3180,"primaryCompletion":3181,"completion":3182,"start":3183,"enrollment":101,"conditions":3184,"interventions":3186},"NCT04334174","Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas",[90],"2022-12-14","2023-02-01","2020-05-29",[3185],"T Cell Lymphoma",[3169],{"trials":3188,"activeCount":101},[],{"trials":3190,"activeCount":101},[],{"trials":3192,"activeCount":101},[],{"intervention":3194,"totalTrials":149,"cells":3195},"Entocort",{"EARLY_PHASE1":3196,"PHASE1":3198,"PHASE2":3200,"PHASE3":3211,"PHASE4":3213,"NA":3215},{"trials":3197,"activeCount":101},[],{"trials":3199,"activeCount":101},[],{"trials":3201,"activeCount":101},[3202],{"nctId":3203,"briefTitle":3204,"status":127,"phases":3205,"primaryCompletion":1920,"completion":1920,"start":3206,"enrollment":32,"conditions":3207,"interventions":3209},"NCT02991768","Budesonide for Mycophenolic Acid-induced Diarrhea in Renal Transplant Recipients",[90],"2017-01-27",[3208],"Diarrhea",[3194,3210],"Placebos",{"trials":3212,"activeCount":101},[],{"trials":3214,"activeCount":101},[],{"trials":3216,"activeCount":101},[],{"intervention":3210,"totalTrials":149,"cells":3218},{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3223,"PHASE3":3229,"PHASE4":3231,"NA":3233},{"trials":3220,"activeCount":101},[],{"trials":3222,"activeCount":101},[],{"trials":3224,"activeCount":101},[3225],{"nctId":3203,"briefTitle":3204,"status":127,"phases":3226,"primaryCompletion":1920,"completion":1920,"start":3206,"enrollment":32,"conditions":3227,"interventions":3228},[90],[3208],[3194,3210],{"trials":3230,"activeCount":101},[],{"trials":3232,"activeCount":101},[],{"trials":3234,"activeCount":101},[],{"intervention":3236,"totalTrials":149,"cells":3237},"Timolol",{"EARLY_PHASE1":3238,"PHASE1":3240,"PHASE2":3242,"PHASE3":3253,"PHASE4":3255,"NA":3257},{"trials":3239,"activeCount":101},[],{"trials":3241,"activeCount":101},[],{"trials":3243,"activeCount":101},[3244],{"nctId":3245,"briefTitle":3246,"status":333,"phases":3247,"primaryCompletion":3248,"completion":3248,"start":3249,"enrollment":766,"conditions":3250,"interventions":3252},"NCT03836664","A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine",[90],"2018-04-14","2017-02-27",[3251],"Migraine",[3236],{"trials":3254,"activeCount":101},[],{"trials":3256,"activeCount":101},[],{"trials":3258,"activeCount":101},[],{"intervention":3260,"totalTrials":149,"cells":3261},"auranofin",{"EARLY_PHASE1":3262,"PHASE1":3264,"PHASE2":3266,"PHASE3":3279,"PHASE4":3281,"NA":3283},{"trials":3263,"activeCount":101},[],{"trials":3265,"activeCount":101},[],{"trials":3267,"activeCount":101},[3268],{"nctId":3269,"briefTitle":3270,"status":333,"phases":3271,"primaryCompletion":3272,"completion":3272,"start":3273,"enrollment":658,"conditions":3274,"interventions":3278},"NCT01419691","Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)",[90],"2015-09","2011-09",[3275,3276,3277],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma","Leukemia, Prolymphocytic",[3260],{"trials":3280,"activeCount":101},[],{"trials":3282,"activeCount":101},[],{"trials":3284,"activeCount":101},[],{"intervention":502,"totalTrials":149,"cells":3286},{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3291,"PHASE3":3297,"PHASE4":3299,"NA":3301},{"trials":3288,"activeCount":101},[],{"trials":3290,"activeCount":101},[],{"trials":3292,"activeCount":101},[3293],{"nctId":492,"briefTitle":493,"status":127,"phases":3294,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":3295,"interventions":3296},[90],[499,500],[502,237,503],{"trials":3298,"activeCount":101},[],{"trials":3300,"activeCount":101},[],{"trials":3302,"activeCount":101},[],{"intervention":503,"totalTrials":149,"cells":3304},{"EARLY_PHASE1":3305,"PHASE1":3307,"PHASE2":3309,"PHASE3":3315,"PHASE4":3317,"NA":3319},{"trials":3306,"activeCount":101},[],{"trials":3308,"activeCount":101},[],{"trials":3310,"activeCount":101},[3311],{"nctId":492,"briefTitle":493,"status":127,"phases":3312,"primaryCompletion":495,"completion":495,"start":496,"enrollment":497,"conditions":3313,"interventions":3314},[90],[499,500],[502,237,503],{"trials":3316,"activeCount":101},[],{"trials":3318,"activeCount":101},[],{"trials":3320,"activeCount":101},[],{"intervention":2576,"totalTrials":149,"cells":3322},{"EARLY_PHASE1":3323,"PHASE1":3325,"PHASE2":3327,"PHASE3":3333,"PHASE4":3335,"NA":3337},{"trials":3324,"activeCount":101},[],{"trials":3326,"activeCount":101},[],{"trials":3328,"activeCount":101},[3329],{"nctId":2569,"briefTitle":2570,"status":127,"phases":3330,"primaryCompletion":2572,"completion":2572,"start":347,"enrollment":27,"conditions":3331,"interventions":3332},[89,90],[2574],[2576,2550],{"trials":3334,"activeCount":101},[],{"trials":3336,"activeCount":101},[],{"trials":3338,"activeCount":101},[],{"intervention":3340,"totalTrials":149,"cells":3341},"Casodex, Zoladex , Lupron",{"EARLY_PHASE1":3342,"PHASE1":3344,"PHASE2":3346,"PHASE3":3356,"PHASE4":3358,"NA":3360},{"trials":3343,"activeCount":101},[],{"trials":3345,"activeCount":101},[],{"trials":3347,"activeCount":101},[3348],{"nctId":3349,"briefTitle":3350,"status":111,"phases":3351,"primaryCompletion":3352,"completion":3352,"start":3353,"enrollment":101,"conditions":3354,"interventions":3355},"NCT02678520","Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients",[90],"2016-02","2015-12",[31],[3340],{"trials":3357,"activeCount":101},[],{"trials":3359,"activeCount":101},[],{"trials":3361,"activeCount":101},[],{"intervention":3363,"totalTrials":149,"cells":3364},"Erlotinib with neoadjuvant chemotherapy",{"EARLY_PHASE1":3365,"PHASE1":3367,"PHASE2":3369,"PHASE3":3380,"PHASE4":3382,"NA":3384},{"trials":3366,"activeCount":101},[],{"trials":3368,"activeCount":101},[],{"trials":3370,"activeCount":101},[3371],{"nctId":3372,"briefTitle":3373,"status":243,"phases":3374,"primaryCompletion":3375,"completion":3376,"start":3377,"enrollment":562,"conditions":3378,"interventions":3379},"NCT00491816","Erlotinib Plus Chemotherapy for Treatment of Triple Negative Breast Cancer",[90],"2014-12","2017-12","2007-07",[15],[3363],{"trials":3381,"activeCount":101},[],{"trials":3383,"activeCount":101},[],{"trials":3385,"activeCount":101},[],{"intervention":3387,"totalTrials":149,"cells":3388},"Lapatinib and RAD-001",{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3393,"PHASE3":3403,"PHASE4":3405,"NA":3407},{"trials":3390,"activeCount":101},[],{"trials":3392,"activeCount":101},[],{"trials":3394,"activeCount":101},[3395],{"nctId":3396,"briefTitle":3397,"status":243,"phases":3398,"primaryCompletion":3399,"completion":469,"start":3400,"enrollment":628,"conditions":3401,"interventions":3402},"NCT01283789","Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer",[90],"2016-04","2011-02",[3064],[3387],{"trials":3404,"activeCount":101},[],{"trials":3406,"activeCount":101},[],{"trials":3408,"activeCount":101},[],{"intervention":2541,"totalTrials":149,"cells":3410},{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3421,"PHASE4":3423,"NA":3425},{"trials":3412,"activeCount":101},[],{"trials":3414,"activeCount":101},[],{"trials":3416,"activeCount":101},[3417],{"nctId":2533,"briefTitle":2534,"status":333,"phases":3418,"primaryCompletion":2479,"completion":2479,"start":2536,"enrollment":1347,"conditions":3419,"interventions":3420},[90],[2538,2539],[2541,2542,2513],{"trials":3422,"activeCount":101},[],{"trials":3424,"activeCount":101},[],{"trials":3426,"activeCount":101},[],{"intervention":2542,"totalTrials":149,"cells":3428},{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3439,"PHASE4":3441,"NA":3443},{"trials":3430,"activeCount":101},[],{"trials":3432,"activeCount":101},[],{"trials":3434,"activeCount":101},[3435],{"nctId":2533,"briefTitle":2534,"status":333,"phases":3436,"primaryCompletion":2479,"completion":2479,"start":2536,"enrollment":1347,"conditions":3437,"interventions":3438},[90],[2538,2539],[2541,2542,2513],{"trials":3440,"activeCount":101},[],{"trials":3442,"activeCount":101},[],{"trials":3444,"activeCount":101},[],{"intervention":3446,"totalTrials":149,"cells":3447},"Omega-3 fatty acid ethyl esters",{"EARLY_PHASE1":3448,"PHASE1":3450,"PHASE2":3452,"PHASE3":3465,"PHASE4":3467,"NA":3469},{"trials":3449,"activeCount":101},[],{"trials":3451,"activeCount":101},[],{"trials":3453,"activeCount":101},[3454],{"nctId":3455,"briefTitle":3456,"status":243,"phases":3457,"primaryCompletion":3458,"completion":3459,"start":3460,"enrollment":16,"conditions":3461,"interventions":3464},"NCT03831698","Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)",[90],"2022-06-08","2024-08","2019-02-06",[3462,3463],"Colorectal Cancer","Lynch Syndrome",[3446],{"trials":3466,"activeCount":101},[],{"trials":3468,"activeCount":101},[],{"trials":3470,"activeCount":101},[],{"intervention":565,"totalTrials":149,"cells":3472},{"EARLY_PHASE1":3473,"PHASE1":3475,"PHASE2":3477,"PHASE3":3483,"PHASE4":3485,"NA":3487},{"trials":3474,"activeCount":101},[],{"trials":3476,"activeCount":101},[],{"trials":3478,"activeCount":101},[3479],{"nctId":556,"briefTitle":557,"status":333,"phases":3480,"primaryCompletion":559,"completion":560,"start":561,"enrollment":562,"conditions":3481,"interventions":3482},[90],[15],[565,566,238,567,568],{"trials":3484,"activeCount":101},[],{"trials":3486,"activeCount":101},[],{"trials":3488,"activeCount":101},[],{"intervention":568,"totalTrials":149,"cells":3490},{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3495,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3492,"activeCount":101},[],{"trials":3494,"activeCount":101},[],{"trials":3496,"activeCount":101},[3497],{"nctId":556,"briefTitle":557,"status":333,"phases":3498,"primaryCompletion":559,"completion":560,"start":561,"enrollment":562,"conditions":3499,"interventions":3500},[90],[15],[565,566,238,567,568],{"trials":3502,"activeCount":101},[],{"trials":3504,"activeCount":101},[],{"trials":3506,"activeCount":101},[],{"intervention":3508,"totalTrials":149,"cells":3509},"PRP Experimental",{"EARLY_PHASE1":3510,"PHASE1":3512,"PHASE2":3514,"PHASE3":3525,"PHASE4":3527,"NA":3529},{"trials":3511,"activeCount":101},[],{"trials":3513,"activeCount":101},[],{"trials":3515,"activeCount":101},[3516],{"nctId":3517,"briefTitle":3518,"status":111,"phases":3519,"primaryCompletion":3520,"completion":3520,"start":3520,"enrollment":101,"conditions":3521,"interventions":3524},"NCT06621342","Platelet Rich Plasma Uterine Infusion",[89,90],"2023-02-16",[3522,3523],"Infertility","Endometriosis",[3508],{"trials":3526,"activeCount":101},[],{"trials":3528,"activeCount":101},[],{"trials":3530,"activeCount":101},[],{"intervention":251,"totalTrials":149,"cells":3532},{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3537,"PHASE3":3543,"PHASE4":3545,"NA":3547},{"trials":3534,"activeCount":101},[],{"trials":3536,"activeCount":101},[],{"trials":3538,"activeCount":101},[3539],{"nctId":241,"briefTitle":242,"status":243,"phases":3540,"primaryCompletion":245,"completion":246,"start":247,"enrollment":190,"conditions":3541,"interventions":3542},[90],[249],[236,237,217,251],{"trials":3544,"activeCount":101},[],{"trials":3546,"activeCount":101},[],{"trials":3548,"activeCount":101},[],{"intervention":3550,"totalTrials":149,"cells":3551},"ATI-450",{"EARLY_PHASE1":3552,"PHASE1":3554,"PHASE2":3556,"PHASE3":3565,"PHASE4":3567,"NA":3569},{"trials":3553,"activeCount":101},[],{"trials":3555,"activeCount":101},[],{"trials":3557,"activeCount":101},[3558],{"nctId":3559,"briefTitle":3560,"status":333,"phases":3561,"primaryCompletion":618,"completion":1654,"start":3562,"enrollment":1347,"conditions":3563,"interventions":3564},"NCT04481685","A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)",[90],"2020-07-20",[1456],[3550],{"trials":3566,"activeCount":101},[],{"trials":3568,"activeCount":101},[],{"trials":3570,"activeCount":101},[],{"intervention":3572,"totalTrials":149,"cells":3573},"Duavee",{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3589,"PHASE4":3591,"NA":3593},{"trials":3575,"activeCount":101},[],{"trials":3577,"activeCount":101},[],{"trials":3579,"activeCount":101},[3580],{"nctId":3581,"briefTitle":3582,"status":333,"phases":3583,"primaryCompletion":3584,"completion":3585,"start":3586,"enrollment":1154,"conditions":3587,"interventions":3588},"NCT02729701","Pilot Study of the Effect of Duavee® on Benign Breast Tissue Proliferation",[90],"2019-01","2019-06","2016-05",[15],[3572],{"trials":3590,"activeCount":101},[],{"trials":3592,"activeCount":101},[],{"trials":3594,"activeCount":101},[],{"intervention":3596,"totalTrials":149,"cells":3597},"Platelet Rich Plasma",{"EARLY_PHASE1":3598,"PHASE1":3600,"PHASE2":3602,"PHASE3":3613,"PHASE4":3615,"NA":3617},{"trials":3599,"activeCount":101},[],{"trials":3601,"activeCount":101},[],{"trials":3603,"activeCount":101},[3604],{"nctId":3605,"briefTitle":3606,"status":127,"phases":3607,"primaryCompletion":3608,"completion":3608,"start":3609,"enrollment":149,"conditions":3610,"interventions":3612},"NCT03837665","Efficacy of Platelet Enriched Plasma in Preventing Surgery for Patients With Chronic Tympanic Membrane Perforation",[89,90],"2019-10-29","2018-05-02",[3611],"Tympanic Membrane Perforation",[3596],{"trials":3614,"activeCount":101},[],{"trials":3616,"activeCount":101},[],{"trials":3618,"activeCount":101},[],{"intervention":3620,"totalTrials":149,"cells":3621},"arzoxifene",{"EARLY_PHASE1":3622,"PHASE1":3624,"PHASE2":3626,"PHASE3":3636,"PHASE4":3638,"NA":3640},{"trials":3623,"activeCount":101},[],{"trials":3625,"activeCount":101},[],{"trials":3627,"activeCount":101},[3628],{"nctId":3629,"briefTitle":3630,"status":333,"phases":3631,"primaryCompletion":3156,"completion":3156,"start":3632,"enrollment":3633,"conditions":3634,"interventions":3635},"NCT00005879","LY353381 in Preventing Breast Cancer in Women With Hyperplasia",[90],"2000-08",199,[15],[3620],{"trials":3637,"activeCount":101},[],{"trials":3639,"activeCount":101},[],{"trials":3641,"activeCount":101},[],{"intervention":3643,"totalTrials":149,"cells":3644},"D-cycloserine",{"EARLY_PHASE1":3645,"PHASE1":3647,"PHASE2":3649,"PHASE3":3659,"PHASE4":3661,"NA":3663},{"trials":3646,"activeCount":101},[],{"trials":3648,"activeCount":101},[],{"trials":3650,"activeCount":101},[3651],{"nctId":3652,"briefTitle":3653,"status":333,"phases":3654,"primaryCompletion":2319,"completion":2319,"start":3655,"enrollment":528,"conditions":3656,"interventions":3658},"NCT00591825","fMRI Study Examining Effects of D-cycloserine in Specific Phobia",[90],"2006-03",[3657],"Phobias",[3643],{"trials":3660,"activeCount":101},[],{"trials":3662,"activeCount":101},[],{"trials":3664,"activeCount":101},[],{"intervention":3666,"totalTrials":149,"cells":3667},"Ranolazine 500 MG",{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3672,"PHASE3":3685,"PHASE4":3687,"NA":3689},{"trials":3669,"activeCount":101},[],{"trials":3671,"activeCount":101},[],{"trials":3673,"activeCount":101},[3674],{"nctId":3675,"briefTitle":3676,"status":333,"phases":3677,"primaryCompletion":3678,"completion":3679,"start":3680,"enrollment":22,"conditions":3681,"interventions":3683},"NCT03472950","Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis",[90],"2020-12-11","2022-12-09","2018-06-11",[3682],"ALS",[3666,3684],"Ranolazine 1000 MG",{"trials":3686,"activeCount":101},[],{"trials":3688,"activeCount":101},[],{"trials":3690,"activeCount":101},[],{"intervention":3684,"totalTrials":149,"cells":3692},{"EARLY_PHASE1":3693,"PHASE1":3695,"PHASE2":3697,"PHASE3":3703,"PHASE4":3705,"NA":3707},{"trials":3694,"activeCount":101},[],{"trials":3696,"activeCount":101},[],{"trials":3698,"activeCount":101},[3699],{"nctId":3675,"briefTitle":3676,"status":333,"phases":3700,"primaryCompletion":3678,"completion":3679,"start":3680,"enrollment":22,"conditions":3701,"interventions":3702},[90],[3682],[3666,3684],{"trials":3704,"activeCount":101},[],{"trials":3706,"activeCount":101},[],{"trials":3708,"activeCount":101},[],{"intervention":3710,"totalTrials":149,"cells":3711},"CoQ10",{"EARLY_PHASE1":3712,"PHASE1":3714,"PHASE2":3716,"PHASE3":3729,"PHASE4":3731,"NA":3733},{"trials":3713,"activeCount":101},[],{"trials":3715,"activeCount":101},[],{"trials":3717,"activeCount":101},[3718],{"nctId":3719,"briefTitle":3720,"status":333,"phases":3721,"primaryCompletion":3722,"completion":3722,"start":3723,"enrollment":3724,"conditions":3725,"interventions":3727},"NCT03133793","CoQ10 and D-ribose in Patients With Diastolic Heart Failure",[90],"2021-03-12","2018-02-05",216,[3726],"Heart Failure, Diastolic",[3710,3728],"D-Ribose Oral Powder",{"trials":3730,"activeCount":101},[],{"trials":3732,"activeCount":101},[],{"trials":3734,"activeCount":101},[],{"intervention":3728,"totalTrials":149,"cells":3736},{"EARLY_PHASE1":3737,"PHASE1":3739,"PHASE2":3741,"PHASE3":3747,"PHASE4":3749,"NA":3751},{"trials":3738,"activeCount":101},[],{"trials":3740,"activeCount":101},[],{"trials":3742,"activeCount":101},[3743],{"nctId":3719,"briefTitle":3720,"status":333,"phases":3744,"primaryCompletion":3722,"completion":3722,"start":3723,"enrollment":3724,"conditions":3745,"interventions":3746},[90],[3726],[3710,3728],{"trials":3748,"activeCount":101},[],{"trials":3750,"activeCount":101},[],{"trials":3752,"activeCount":101},[],{"intervention":3754,"totalTrials":149,"cells":3755},"Mitomycin c",{"EARLY_PHASE1":3756,"PHASE1":3758,"PHASE2":3760,"PHASE3":3773,"PHASE4":3775,"NA":3777},{"trials":3757,"activeCount":101},[],{"trials":3759,"activeCount":101},[],{"trials":3761,"activeCount":101},[3762],{"nctId":3763,"briefTitle":3764,"status":243,"phases":3765,"primaryCompletion":3766,"completion":2493,"start":3767,"enrollment":486,"conditions":3768,"interventions":3771},"NCT03073694","Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis",[90],"2024-07","2017-07-14",[3769,3770],"Cancer, Appendiceal","ColoRectal Cancer",[3754,3772],"Melphalan",{"trials":3774,"activeCount":101},[],{"trials":3776,"activeCount":101},[],{"trials":3778,"activeCount":101},[],{"intervention":3772,"totalTrials":149,"cells":3780},{"EARLY_PHASE1":3781,"PHASE1":3783,"PHASE2":3785,"PHASE3":3791,"PHASE4":3793,"NA":3795},{"trials":3782,"activeCount":101},[],{"trials":3784,"activeCount":101},[],{"trials":3786,"activeCount":101},[3787],{"nctId":3763,"briefTitle":3764,"status":243,"phases":3788,"primaryCompletion":3766,"completion":2493,"start":3767,"enrollment":486,"conditions":3789,"interventions":3790},[90],[3769,3770],[3754,3772],{"trials":3792,"activeCount":101},[],{"trials":3794,"activeCount":101},[],{"trials":3796,"activeCount":101},[],{"intervention":3798,"totalTrials":149,"cells":3799},"IV Vitamin C",{"EARLY_PHASE1":3800,"PHASE1":3802,"PHASE2":3813,"PHASE3":3815,"PHASE4":3817,"NA":3819},{"trials":3801,"activeCount":101},[],{"trials":3803,"activeCount":101},[3804],{"nctId":3805,"briefTitle":3806,"status":333,"phases":3807,"primaryCompletion":3808,"completion":3808,"start":3809,"enrollment":284,"conditions":3810,"interventions":3812},"NCT01833351","Evaluation of Intravenous Ascorbic Acid",[89],"2015-10","2011-05",[3811],"Safety and Pharmacokinetics of Intravenous Ascorbate",[3798,3798],{"trials":3814,"activeCount":101},[],{"trials":3816,"activeCount":101},[],{"trials":3818,"activeCount":101},[],{"trials":3820,"activeCount":101},[],{"intervention":3822,"totalTrials":149,"cells":3823},"Inhaled nebulized milrinone",{"EARLY_PHASE1":3824,"PHASE1":3826,"PHASE2":3838,"PHASE3":3840,"PHASE4":3842,"NA":3844},{"trials":3825,"activeCount":101},[],{"trials":3827,"activeCount":101},[3828],{"nctId":3829,"briefTitle":3830,"status":333,"phases":3831,"primaryCompletion":3832,"completion":3832,"start":3833,"enrollment":1306,"conditions":3834,"interventions":3837},"NCT02077010","Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population",[89],"2023-01-24","2020-06-15",[3835,3836],"Heart Failure","Cardiomyopathy",[3822],{"trials":3839,"activeCount":101},[],{"trials":3841,"activeCount":101},[],{"trials":3843,"activeCount":101},[],{"trials":3845,"activeCount":101},[],{"intervention":2565,"totalTrials":149,"cells":3847},{"EARLY_PHASE1":3848,"PHASE1":3850,"PHASE2":3856,"PHASE3":3858,"PHASE4":3860,"NA":3862},{"trials":3849,"activeCount":101},[],{"trials":3851,"activeCount":101},[3852],{"nctId":2557,"briefTitle":2558,"status":127,"phases":3853,"primaryCompletion":2560,"completion":2560,"start":2561,"enrollment":149,"conditions":3854,"interventions":3855},[89],[2563],[2550,2565],{"trials":3857,"activeCount":101},[],{"trials":3859,"activeCount":101},[],{"trials":3861,"activeCount":101},[],{"trials":3863,"activeCount":101},[],{"intervention":3865,"totalTrials":149,"cells":3866},"Copaxone",{"EARLY_PHASE1":3867,"PHASE1":3869,"PHASE2":3881,"PHASE3":3883,"PHASE4":3885,"NA":3887},{"trials":3868,"activeCount":101},[],{"trials":3870,"activeCount":101},[3871],{"nctId":3872,"briefTitle":3873,"status":243,"phases":3874,"primaryCompletion":3875,"completion":3766,"start":3876,"enrollment":1306,"conditions":3877,"interventions":3880},"NCT03982212","A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors",[89],"2022-12-07","2019-07-26",[3878,2563,3879],"Cutaneous Squamous Cell Carcinoma","Basal Cell Carcinoma",[3865],{"trials":3882,"activeCount":101},[],{"trials":3884,"activeCount":101},[],{"trials":3886,"activeCount":101},[],{"trials":3888,"activeCount":101},[],{"intervention":3890,"totalTrials":149,"cells":3891},"arzoxifene hydrochloride",{"EARLY_PHASE1":3892,"PHASE1":3894,"PHASE2":3905,"PHASE3":3907,"PHASE4":3909,"NA":3911},{"trials":3893,"activeCount":101},[],{"trials":3895,"activeCount":101},[3896],{"nctId":3897,"briefTitle":3898,"status":333,"phases":3899,"primaryCompletion":3900,"completion":3900,"start":3901,"conditions":3902,"interventions":3903},"NCT00005886","Tamoxifen Compared With LY353381 in Treating Women With Newly Diagnosed Breast Cancer",[89],"2002-08","2000-07",[15],[3890,3904],"tamoxifen citrate",{"trials":3906,"activeCount":101},[],{"trials":3908,"activeCount":101},[],{"trials":3910,"activeCount":101},[],{"trials":3912,"activeCount":101},[],{"intervention":3904,"totalTrials":149,"cells":3914},{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3923,"PHASE3":3925,"PHASE4":3927,"NA":3929},{"trials":3916,"activeCount":101},[],{"trials":3918,"activeCount":101},[3919],{"nctId":3897,"briefTitle":3898,"status":333,"phases":3920,"primaryCompletion":3900,"completion":3900,"start":3901,"conditions":3921,"interventions":3922},[89],[15],[3890,3904],{"trials":3924,"activeCount":101},[],{"trials":3926,"activeCount":101},[],{"trials":3928,"activeCount":101},[],{"trials":3930,"activeCount":101},[],{"intervention":3932,"totalTrials":149,"cells":3933},"Indole-3-carbinol",{"EARLY_PHASE1":3934,"PHASE1":3936,"PHASE2":3945,"PHASE3":3947,"PHASE4":3949,"NA":3951},{"trials":3935,"activeCount":101},[],{"trials":3937,"activeCount":101},[3938],{"nctId":3939,"briefTitle":3940,"status":333,"phases":3941,"primaryCompletion":3156,"start":3942,"enrollment":19,"conditions":3943,"interventions":3944},"NCT00033345","Indole-3-Carbinol in Preventing Breast Cancer in Nonsmoking Women Who Are at High Risk For Breast Cancer",[89],"2002-01",[15],[3932,3932],{"trials":3946,"activeCount":101},[],{"trials":3948,"activeCount":101},[],{"trials":3950,"activeCount":101},[],{"trials":3952,"activeCount":101},[],{"intervention":3954,"totalTrials":149,"cells":3955},"Phenylbutyrate Oral",{"EARLY_PHASE1":3956,"PHASE1":3958,"PHASE2":3969,"PHASE3":3971,"PHASE4":3973,"NA":3975},{"trials":3957,"activeCount":101},[],{"trials":3959,"activeCount":101},[3960],{"nctId":3961,"briefTitle":3962,"status":333,"phases":3963,"primaryCompletion":3964,"completion":3964,"start":3965,"enrollment":1306,"conditions":3966,"interventions":3968},"NCT04421677","Safety and Tolerability of Phenylbutyrate in Inclusion Body Myositis",[89],"2022-01-20","2020-08-20",[403,3967],"Sporadic Inclusion Body Myositis",[3954],{"trials":3970,"activeCount":101},[],{"trials":3972,"activeCount":101},[],{"trials":3974,"activeCount":101},[],{"trials":3976,"activeCount":101},[],{"intervention":3978,"totalTrials":149,"cells":3979},"MSCTC-0010 Dose Escalation",{"EARLY_PHASE1":3980,"PHASE1":3982,"PHASE2":3993,"PHASE3":3995,"PHASE4":3997,"NA":3999},{"trials":3981,"activeCount":101},[],{"trials":3983,"activeCount":101},[3984],{"nctId":3985,"briefTitle":3986,"status":333,"phases":3987,"primaryCompletion":3988,"completion":3988,"start":3989,"enrollment":1094,"conditions":3990,"interventions":3992},"NCT03158896","Evaluation of Umbilical Cord-Derived Wharton's Jelly Stem Cells for the Treatment of Acute Graft Versus Host Disease",[89],"2025-12-08","2018-07-09",[3991],"Acute Graft Versus Host Disease",[3978],{"trials":3994,"activeCount":101},[],{"trials":3996,"activeCount":101},[],{"trials":3998,"activeCount":101},[],{"trials":4000,"activeCount":101},[],{"intervention":4002,"totalTrials":149,"cells":4003},"Lithium Carbonate",{"EARLY_PHASE1":4004,"PHASE1":4006,"PHASE2":4014,"PHASE3":4016,"PHASE4":4018,"NA":4020},{"trials":4005,"activeCount":101},[],{"trials":4007,"activeCount":101},[4008],{"nctId":4009,"briefTitle":4010,"status":333,"phases":4011,"primaryCompletion":468,"completion":468,"start":1718,"enrollment":27,"conditions":4012,"interventions":4013},"NCT02198859","Evaluation of Lithium and It's Effect on Clinically Localized Prostate Cancer",[89],[31],[4002],{"trials":4015,"activeCount":101},[],{"trials":4017,"activeCount":101},[],{"trials":4019,"activeCount":101},[],{"trials":4021,"activeCount":101},[],{"intervention":4023,"totalTrials":149,"cells":4024},"Alianza Latina",{"EARLY_PHASE1":4025,"PHASE1":4027,"PHASE2":4037,"PHASE3":4039,"PHASE4":4041,"NA":4043},{"trials":4026,"activeCount":101},[],{"trials":4028,"activeCount":101},[4029],{"nctId":4030,"briefTitle":4031,"status":333,"phases":4032,"primaryCompletion":4033,"completion":4033,"start":1464,"enrollment":4034,"conditions":4035,"interventions":4036},"NCT04418232","Feasibility of a Systems Approach for Alzheimer's Services Among Latinos Attending Primary Care Practices",[89],"2024-08-20",243,[29],[4023],{"trials":4038,"activeCount":101},[],{"trials":4040,"activeCount":101},[],{"trials":4042,"activeCount":101},[],{"trials":4044,"activeCount":101},[],{"intervention":4046,"totalTrials":149,"cells":4047},"Irinotecan",{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4059,"PHASE3":4061,"PHASE4":4063,"NA":4065},{"trials":4049,"activeCount":101},[],{"trials":4051,"activeCount":101},[4052],{"nctId":4053,"briefTitle":4054,"status":333,"phases":4055,"primaryCompletion":1718,"completion":3808,"start":3400,"enrollment":1347,"conditions":4056,"interventions":4057},"NCT01304602","A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer",[89],[3462],[4046,4058],"BKM120",{"trials":4060,"activeCount":101},[],{"trials":4062,"activeCount":101},[],{"trials":4064,"activeCount":101},[],{"trials":4066,"activeCount":101},[],{"intervention":4058,"totalTrials":149,"cells":4068},{"EARLY_PHASE1":4069,"PHASE1":4071,"PHASE2":4077,"PHASE3":4079,"PHASE4":4081,"NA":4083},{"trials":4070,"activeCount":101},[],{"trials":4072,"activeCount":101},[4073],{"nctId":4053,"briefTitle":4054,"status":333,"phases":4074,"primaryCompletion":1718,"completion":3808,"start":3400,"enrollment":1347,"conditions":4075,"interventions":4076},[89],[3462],[4046,4058],{"trials":4078,"activeCount":101},[],{"trials":4080,"activeCount":101},[],{"trials":4082,"activeCount":101},[],{"trials":4084,"activeCount":101},[],{"intervention":4086,"totalTrials":356,"cells":4087},"Osanetant",{"EARLY_PHASE1":4088,"PHASE1":4107,"PHASE2":4109,"PHASE3":4111,"PHASE4":4113,"NA":4115},{"trials":4089,"activeCount":101},[4090,4100],{"nctId":4091,"briefTitle":4092,"status":127,"phases":4093,"primaryCompletion":4094,"completion":4095,"start":4096,"enrollment":149,"conditions":4097,"interventions":4099},"NCT05607342","Pilot of Osanetant to Reduce Testosterone in Men With Adenocarcinoma of the Prostate",[88],"2023-09-22","2023-11-06","2023-01-03",[4098],"Prostate Adenocarcinoma",[4086],{"nctId":4101,"briefTitle":4102,"status":111,"phases":4103,"primaryCompletion":4094,"completion":4104,"start":4096,"enrollment":101,"conditions":4105,"interventions":4106},"NCT05647447","Pilot of Osanetant to Reduce Severity of Hot Flashes in Men With Adenocarcinoma of the Prostate",[88],"2023-10-05",[4098],[4086],{"trials":4108,"activeCount":101},[],{"trials":4110,"activeCount":101},[],{"trials":4112,"activeCount":101},[],{"trials":4114,"activeCount":101},[],{"trials":4116,"activeCount":101},[],{"intervention":2483,"totalTrials":149,"cells":4118},{"EARLY_PHASE1":4119,"PHASE1":4125,"PHASE2":4127,"PHASE3":4129,"PHASE4":4131,"NA":4133},{"trials":4120,"activeCount":101},[4121],{"nctId":2475,"briefTitle":2476,"status":333,"phases":4122,"primaryCompletion":1718,"completion":2478,"start":2479,"enrollment":19,"conditions":4123,"interventions":4124},[88],[2481],[2470,2483],{"trials":4126,"activeCount":101},[],{"trials":4128,"activeCount":101},[],{"trials":4130,"activeCount":101},[],{"trials":4132,"activeCount":101},[],{"trials":4134,"activeCount":101},[],{"intervention":4136,"totalTrials":149,"cells":4137},"bortezomib and G-CSF",{"EARLY_PHASE1":4138,"PHASE1":4150,"PHASE2":4152,"PHASE3":4154,"PHASE4":4156,"NA":4158},{"trials":4139,"activeCount":101},[4140],{"nctId":4141,"briefTitle":4142,"status":333,"phases":4143,"primaryCompletion":4144,"completion":3375,"start":4145,"enrollment":16,"conditions":4146,"interventions":4149},"NCT01171092","A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma",[88],"2013-01","2010-09",[4147,4148],"Malignant Lymphoma, Stem Cell Type","Autologous Transplant",[4136],{"trials":4151,"activeCount":101},[],{"trials":4153,"activeCount":101},[],{"trials":4155,"activeCount":101},[],{"trials":4157,"activeCount":101},[],{"trials":4159,"activeCount":101},[],{"intervention":4161,"totalTrials":149,"cells":4162},"Hydralazine",{"EARLY_PHASE1":4163,"PHASE1":4174,"PHASE2":4176,"PHASE3":4178,"PHASE4":4180,"NA":4182},{"trials":4164,"activeCount":101},[4165],{"nctId":4166,"briefTitle":4167,"status":333,"phases":4168,"primaryCompletion":4169,"completion":4169,"start":4170,"enrollment":22,"conditions":4171,"interventions":4173},"NCT03423810","Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients",[88],"2020-01-30","2018-04-23",[4172],"Polycystic Kidney Diseases",[4161],{"trials":4175,"activeCount":101},[],{"trials":4177,"activeCount":101},[],{"trials":4179,"activeCount":101},[],{"trials":4181,"activeCount":101},[],{"trials":4183,"activeCount":101},[],{"intervention":4185,"totalTrials":149,"cells":4186},"extracorporeal photopheresis",{"EARLY_PHASE1":4187,"PHASE1":4200,"PHASE2":4202,"PHASE3":4204,"PHASE4":4206,"NA":4208},{"trials":4188,"activeCount":101},[4189],{"nctId":4190,"briefTitle":4191,"status":333,"phases":4192,"primaryCompletion":4193,"completion":2478,"start":4194,"enrollment":4195,"conditions":4196,"interventions":4199},"NCT01174940","Test Extracorporeal Photopheresis (ECP) Treatment Before\u002FAfter Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease",[88],"2014-08","2010-06",22,[4197,4198],"Stem Cell Leukemia of Unclear Lineage","Graft Versus Host Disease",[4185],{"trials":4201,"activeCount":101},[],{"trials":4203,"activeCount":101},[],{"trials":4205,"activeCount":101},[],{"trials":4207,"activeCount":101},[],{"trials":4209,"activeCount":101},[],{"intervention":4211,"totalTrials":149,"cells":4212},"Birth control",{"EARLY_PHASE1":4213,"PHASE1":4224,"PHASE2":4226,"PHASE3":4228,"PHASE4":4230,"NA":4232},{"trials":4214,"activeCount":101},[4215],{"nctId":4216,"briefTitle":4217,"status":333,"phases":4218,"primaryCompletion":4219,"completion":4219,"start":1644,"enrollment":32,"conditions":4220,"interventions":4222},"NCT01396369","Flaxseed Lignan (Brevail)",[88],"2013-12",[4221],"Polycystic Ovarian Syndrome",[4211,4223],"Birth control plus Brevail",{"trials":4225,"activeCount":101},[],{"trials":4227,"activeCount":101},[],{"trials":4229,"activeCount":101},[],{"trials":4231,"activeCount":101},[],{"trials":4233,"activeCount":101},[],{"intervention":4223,"totalTrials":149,"cells":4235},{"EARLY_PHASE1":4236,"PHASE1":4242,"PHASE2":4244,"PHASE3":4246,"PHASE4":4248,"NA":4250},{"trials":4237,"activeCount":101},[4238],{"nctId":4216,"briefTitle":4217,"status":333,"phases":4239,"primaryCompletion":4219,"completion":4219,"start":1644,"enrollment":32,"conditions":4240,"interventions":4241},[88],[4221],[4211,4223],{"trials":4243,"activeCount":101},[],{"trials":4245,"activeCount":101},[],{"trials":4247,"activeCount":101},[],{"trials":4249,"activeCount":101},[],{"trials":4251,"activeCount":101},[],{"intervention":4253,"totalTrials":356,"cells":4254},"Tacrolimus",{"EARLY_PHASE1":4255,"PHASE1":4257,"PHASE2":4259,"PHASE3":4261,"PHASE4":4263,"NA":4265},{"trials":4256,"activeCount":101},[],{"trials":4258,"activeCount":101},[],{"trials":4260,"activeCount":101},[],{"trials":4262,"activeCount":101},[],{"trials":4264,"activeCount":101},[],{"trials":4266,"activeCount":101},[4267,4277],{"nctId":4268,"briefTitle":4269,"status":333,"phases":4270,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":948,"conditions":4273,"interventions":4275},"NCT03703154","Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Immediate Release Tacrolimus to Slow Release Envarsus",[],"2021-03-03","2018-10-25",[4274],"End Stage Renal Disease",[4276,4253],"Envarsus",{"nctId":4278,"briefTitle":4279,"status":333,"phases":4280,"primaryCompletion":4281,"completion":4282,"start":1590,"enrollment":948,"conditions":4283,"interventions":4284},"NCT03413722","Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus",[],"2021-08-01","2022-10-01",[4274],[4253,4285],"Everolimus",{"intervention":4287,"totalTrials":149,"cells":4288},"Methylprednisolone and Lidocaine",{"EARLY_PHASE1":4289,"PHASE1":4291,"PHASE2":4293,"PHASE3":4295,"PHASE4":4297,"NA":4299},{"trials":4290,"activeCount":101},[],{"trials":4292,"activeCount":101},[],{"trials":4294,"activeCount":101},[],{"trials":4296,"activeCount":101},[],{"trials":4298,"activeCount":101},[],{"trials":4300,"activeCount":101},[4301],{"nctId":4302,"briefTitle":4303,"status":333,"phases":4304,"primaryCompletion":4305,"completion":4306,"start":4307,"enrollment":766,"conditions":4308,"interventions":4310},"NCT00682357","Effect of Intraarticular Steroids on Bone Turnover in Osteoarthritis",[93],"2009-11","2010-05","2008-05",[4309],"Osteoarthritis",[4287,4287],{"intervention":4312,"totalTrials":149,"cells":4313},"E-cigarette and Heat not burn",{"EARLY_PHASE1":4314,"PHASE1":4316,"PHASE2":4318,"PHASE3":4320,"PHASE4":4322,"NA":4324},{"trials":4315,"activeCount":101},[],{"trials":4317,"activeCount":101},[],{"trials":4319,"activeCount":101},[],{"trials":4321,"activeCount":101},[],{"trials":4323,"activeCount":101},[],{"trials":4325,"activeCount":101},[4326],{"nctId":4327,"briefTitle":4328,"status":333,"phases":4329,"primaryCompletion":4330,"completion":4330,"start":4331,"enrollment":4195,"conditions":4332,"interventions":4333},"NCT04646668","Comparative Abuse Liability Among African American and White Smokers",[93],"2021-08-26","2020-09-21",[1544],[4312],{"intervention":4335,"totalTrials":149,"cells":4336},"Blood sample",{"EARLY_PHASE1":4337,"PHASE1":4339,"PHASE2":4341,"PHASE3":4343,"PHASE4":4345,"NA":4347},{"trials":4338,"activeCount":101},[],{"trials":4340,"activeCount":101},[],{"trials":4342,"activeCount":101},[],{"trials":4344,"activeCount":101},[],{"trials":4346,"activeCount":101},[],{"trials":4348,"activeCount":101},[4349],{"nctId":4350,"briefTitle":4351,"status":111,"phases":4352,"primaryCompletion":3400,"completion":3400,"start":4145,"enrollment":101,"conditions":4353,"interventions":4354},"NCT01176422","Telomere and Telomerase",[],[1247],[4335],{"intervention":4356,"totalTrials":149,"cells":4357},"tirzepatide",{"EARLY_PHASE1":4358,"PHASE1":4360,"PHASE2":4362,"PHASE3":4364,"PHASE4":4366,"NA":4368},{"trials":4359,"activeCount":101},[],{"trials":4361,"activeCount":101},[],{"trials":4363,"activeCount":101},[],{"trials":4365,"activeCount":101},[],{"trials":4367,"activeCount":101},[],{"trials":4369,"activeCount":101},[4370],{"nctId":4371,"briefTitle":4372,"status":333,"phases":4373,"primaryCompletion":4374,"completion":4374,"start":4375,"enrollment":766,"conditions":4376,"interventions":4378},"NCT06485089","Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers",[],"2026-03-25","2024-09-14",[18,4377],"Breast Cancer Risk",[4356],{"intervention":4380,"totalTrials":149,"cells":4381},"Thrombin-JMI",{"EARLY_PHASE1":4382,"PHASE1":4384,"PHASE2":4386,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4383,"activeCount":101},[],{"trials":4385,"activeCount":101},[],{"trials":4387,"activeCount":101},[],{"trials":4389,"activeCount":101},[],{"trials":4391,"activeCount":101},[],{"trials":4393,"activeCount":101},[4394],{"nctId":4395,"briefTitle":4396,"status":127,"phases":4397,"primaryCompletion":4398,"completion":4398,"start":4399,"enrollment":149,"conditions":4400,"interventions":4402},"NCT00814333","Trial Comparing Outcomes With Merocel Packing or Thrombin-JMI for Anterior Epistaxis",[93],"2011-08","2008-12",[4401],"Epistaxis",[4380,4403],"Merocel pack",{"intervention":4403,"totalTrials":149,"cells":4405},{"EARLY_PHASE1":4406,"PHASE1":4408,"PHASE2":4410,"PHASE3":4412,"PHASE4":4414,"NA":4416},{"trials":4407,"activeCount":101},[],{"trials":4409,"activeCount":101},[],{"trials":4411,"activeCount":101},[],{"trials":4413,"activeCount":101},[],{"trials":4415,"activeCount":101},[],{"trials":4417,"activeCount":101},[4418],{"nctId":4395,"briefTitle":4396,"status":127,"phases":4419,"primaryCompletion":4398,"completion":4398,"start":4399,"enrollment":149,"conditions":4420,"interventions":4421},[93],[4401],[4380,4403],{"intervention":4276,"totalTrials":149,"cells":4423},{"EARLY_PHASE1":4424,"PHASE1":4426,"PHASE2":4428,"PHASE3":4430,"PHASE4":4432,"NA":4434},{"trials":4425,"activeCount":101},[],{"trials":4427,"activeCount":101},[],{"trials":4429,"activeCount":101},[],{"trials":4431,"activeCount":101},[],{"trials":4433,"activeCount":101},[],{"trials":4435,"activeCount":101},[4436],{"nctId":4268,"briefTitle":4269,"status":333,"phases":4437,"primaryCompletion":4271,"completion":4271,"start":4272,"enrollment":948,"conditions":4438,"interventions":4439},[],[4274],[4276,4253],{"intervention":4441,"totalTrials":149,"cells":4442},"Metformin",{"EARLY_PHASE1":4443,"PHASE1":4445,"PHASE2":4447,"PHASE3":4449,"PHASE4":4451,"NA":4453},{"trials":4444,"activeCount":101},[],{"trials":4446,"activeCount":101},[],{"trials":4448,"activeCount":101},[],{"trials":4450,"activeCount":101},[],{"trials":4452,"activeCount":101},[],{"trials":4454,"activeCount":101},[4455],{"nctId":4456,"briefTitle":4457,"status":111,"phases":4458,"primaryCompletion":4459,"completion":2251,"start":347,"enrollment":101,"conditions":4460,"interventions":4462},"NCT00536211","Physical Inactivity and Insulin Resistance in Skeletal Muscle.",[93],"2011-10",[4461,1201,34,2254,18],"Metabolic Syndrome X",[4441],{"intervention":4464,"totalTrials":149,"cells":4465},"Statin",{"EARLY_PHASE1":4466,"PHASE1":4468,"PHASE2":4470,"PHASE3":4472,"PHASE4":4474,"NA":4476},{"trials":4467,"activeCount":101},[],{"trials":4469,"activeCount":101},[],{"trials":4471,"activeCount":101},[],{"trials":4473,"activeCount":101},[],{"trials":4475,"activeCount":101},[],{"trials":4477,"activeCount":101},[4478],{"nctId":4479,"briefTitle":4480,"status":333,"phases":4481,"primaryCompletion":3809,"completion":3809,"start":4482,"enrollment":4483,"conditions":4484,"interventions":4488},"NCT01700530","Exercise, Statins, and the Metabolic Syndrome",[93],"2007-05",121,[4485,4486,4487],"Metabolic Syndrome","Obese","Sedentary",[4464],{"intervention":4490,"totalTrials":149,"cells":4491},"Cholecalciferol - CKD",{"EARLY_PHASE1":4492,"PHASE1":4494,"PHASE2":4496,"PHASE3":4498,"PHASE4":4500,"NA":4502},{"trials":4493,"activeCount":101},[],{"trials":4495,"activeCount":101},[],{"trials":4497,"activeCount":101},[],{"trials":4499,"activeCount":101},[],{"trials":4501,"activeCount":101},[],{"trials":4503,"activeCount":101},[4504],{"nctId":4505,"briefTitle":4506,"status":333,"phases":4507,"primaryCompletion":470,"completion":470,"start":4508,"enrollment":4509,"conditions":4510,"interventions":4513},"NCT01222234","Impact of Vitamin D Therapies on Chronic Kidney Disease",[93],"2010-10",56,[4511,4512],"Chronic Kidney Disease (CKD)","End-stage Renal Disease (ESRD)",[4490,4514],"Cholecalciferol - non-CKD",{"intervention":4514,"totalTrials":149,"cells":4516},{"EARLY_PHASE1":4517,"PHASE1":4519,"PHASE2":4521,"PHASE3":4523,"PHASE4":4525,"NA":4527},{"trials":4518,"activeCount":101},[],{"trials":4520,"activeCount":101},[],{"trials":4522,"activeCount":101},[],{"trials":4524,"activeCount":101},[],{"trials":4526,"activeCount":101},[],{"trials":4528,"activeCount":101},[4529],{"nctId":4505,"briefTitle":4506,"status":333,"phases":4530,"primaryCompletion":470,"completion":470,"start":4508,"enrollment":4509,"conditions":4531,"interventions":4532},[93],[4511,4512],[4490,4514],{"intervention":4534,"totalTrials":149,"cells":4535},"COVID-19 Vaccine",{"EARLY_PHASE1":4536,"PHASE1":4538,"PHASE2":4540,"PHASE3":4542,"PHASE4":4544,"NA":4546},{"trials":4537,"activeCount":101},[],{"trials":4539,"activeCount":101},[],{"trials":4541,"activeCount":101},[],{"trials":4543,"activeCount":101},[],{"trials":4545,"activeCount":101},[],{"trials":4547,"activeCount":101},[4548],{"nctId":4549,"briefTitle":4550,"status":243,"phases":4551,"primaryCompletion":4552,"completion":4553,"start":4554,"enrollment":327,"conditions":4555,"interventions":4558},"NCT04821570","To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment",[],"2024-03-28","2025-03-28","2021-02-23",[15,4556,4557],"Lung Cancer","Melanoma (Skin)",[4534],{"intervention":4285,"totalTrials":149,"cells":4560},{"EARLY_PHASE1":4561,"PHASE1":4563,"PHASE2":4565,"PHASE3":4567,"PHASE4":4569,"NA":4571},{"trials":4562,"activeCount":101},[],{"trials":4564,"activeCount":101},[],{"trials":4566,"activeCount":101},[],{"trials":4568,"activeCount":101},[],{"trials":4570,"activeCount":101},[],{"trials":4572,"activeCount":101},[4573],{"nctId":4278,"briefTitle":4279,"status":333,"phases":4574,"primaryCompletion":4281,"completion":4282,"start":1590,"enrollment":948,"conditions":4575,"interventions":4576},[],[4274],[4253,4285],{"intervention":4578,"totalTrials":149,"cells":4579},"Botulinum Toxin Type A Injection [Botox]",{"EARLY_PHASE1":4580,"PHASE1":4582,"PHASE2":4584,"PHASE3":4586,"PHASE4":4588,"NA":4590},{"trials":4581,"activeCount":101},[],{"trials":4583,"activeCount":101},[],{"trials":4585,"activeCount":101},[],{"trials":4587,"activeCount":101},[],{"trials":4589,"activeCount":101},[],{"trials":4591,"activeCount":101},[4592],{"nctId":4593,"briefTitle":4594,"status":111,"phases":4595,"primaryCompletion":4596,"completion":4597,"start":4598,"enrollment":101,"conditions":4599,"interventions":4601},"NCT04938102","Role of EndoFLIP in the Diagnostic Paradigm of Esophagogastric Junction Outflow Obstruction",[93],"2023-07","2024-10-11","2022-07",[4600],"Esophagogastric Junction Disorder",[4578]]